

WEBVTT

NOTE duration:"01:06:27"

NOTE recognizability:0.828

NOTE language:en-us

NOTE Confidence: 0.787287484615385

00:00:00.000 --> 00:00:02.352 Thanks for joining for the fourth

NOTE Confidence: 0.787287484615385

00:00:02.352 --> 00:00:04.852 session of the weekly Yale Cancer

NOTE Confidence: 0.787287484615385

00:00:04.852 --> 00:00:07.940 Center 2023 post Ash CME review.

NOTE Confidence: 0.787287484615385

00:00:07.940 --> 00:00:09.870 Today we'll be going over

NOTE Confidence: 0.787287484615385

00:00:09.870 --> 00:00:11.800 lymphoma and I'm Scott Huntington,

NOTE Confidence: 0.787287484615385

00:00:11.800 --> 00:00:13.648 lymphoma specialist here and I had

NOTE Confidence: 0.787287484615385

00:00:13.648 --> 00:00:15.347 the distinct pleasure of introducing

NOTE Confidence: 0.787287484615385

00:00:15.347 --> 00:00:16.979 our three presenters today.

NOTE Confidence: 0.787287484615385

00:00:16.980 --> 00:00:19.818 Our first presenter is Francesca Montanari,

NOTE Confidence: 0.787287484615385

00:00:19.820 --> 00:00:22.494 who will be presenting an indolent lymphomas.

NOTE Confidence: 0.787287484615385

00:00:22.500 --> 00:00:24.690 Dr. Shalon Cathari will go next

NOTE Confidence: 0.787287484615385

00:00:24.690 --> 00:00:26.620 and present aggressive B cell

NOTE Confidence: 0.787287484615385

00:00:26.620 --> 00:00:28.640 lymphomas and then doctor Tarsin

NOTE Confidence: 0.787287484615385

00:00:28.640 --> 00:00:30.780 Sethi will be presenting T cell.  
NOTE Confidence: 0.787287484615385

00:00:30.780 --> 00:00:32.555 Performance and harsh gonna follow  
NOTE Confidence: 0.787287484615385

00:00:32.555 --> 00:00:35.112 the rest of the lymphoma group is  
NOTE Confidence: 0.787287484615385

00:00:35.112 --> 00:00:36.917 pictured here including Doctor Sufi  
NOTE Confidence: 0.787287484615385

00:00:36.917 --> 00:00:39.173 and Doctor Foss who see lymphoma  
NOTE Confidence: 0.787287484615385

00:00:39.173 --> 00:00:41.128 but also do cellular therapeutics.  
NOTE Confidence: 0.787287484615385

00:00:41.130 --> 00:00:44.058 And then Doctor Seropian is really  
NOTE Confidence: 0.787287484615385

00:00:44.058 --> 00:00:46.515 fixed in terms of his clinical  
NOTE Confidence: 0.787287484615385

00:00:46.515 --> 00:00:48.087 practice on cellular therapeutics.  
NOTE Confidence: 0.787287484615385

00:00:48.090 --> 00:00:51.310 But this is the broad group here  
NOTE Confidence: 0.787287484615385

00:00:51.310 --> 00:00:53.261 including Doctor Montanari who  
NOTE Confidence: 0.787287484615385

00:00:53.261 --> 00:00:55.726 sees patients at Smilow Greenwich.  
NOTE Confidence: 0.787287484615385

00:00:55.730 --> 00:00:57.767 So I think we'll move to the  
NOTE Confidence: 0.787287484615385

00:00:57.767 --> 00:00:59.550 remainder of the presentation.  
NOTE Confidence: 0.787287484615385

00:00:59.550 --> 00:01:00.552 If there's additional  
NOTE Confidence: 0.787287484615385

00:01:00.552 --> 00:01:01.888 questions that you have,

NOTE Confidence: 0.787287484615385  
00:01:01.890 --> 00:01:03.264 please use the chat feature or  
NOTE Confidence: 0.787287484615385  
00:01:03.264 --> 00:01:04.849 question and answer and we hope to  
NOTE Confidence: 0.787287484615385  
00:01:04.849 --> 00:01:05.889 have about 10 minute discussion  
NOTE Confidence: 0.787287484615385  
00:01:05.889 --> 00:01:07.408 at the end of this presentation.  
NOTE Confidence: 0.699771686666667  
00:01:17.940 --> 00:01:21.858 Doctor Montanari mute. Those things happen.  
NOTE Confidence: 0.728307406666667  
00:01:23.450 --> 00:01:24.128 Sorry about that.  
NOTE Confidence: 0.819620173809524  
00:01:24.540 --> 00:01:27.109 I'll start sharing with you my selection  
NOTE Confidence: 0.819620173809524  
00:01:27.109 --> 00:01:29.782 of abstract of indolent lymphomas and I  
NOTE Confidence: 0.819620173809524  
00:01:29.782 --> 00:01:32.700 have no conflict of interest to disclose.  
NOTE Confidence: 0.819620173809524  
00:01:32.700 --> 00:01:34.340 This is my abstract selection.  
NOTE Confidence: 0.819620173809524  
00:01:34.340 --> 00:01:36.559 We'll start, we'll space from first line,  
NOTE Confidence: 0.819620173809524  
00:01:36.560 --> 00:01:39.560 second line by specific antibodies,  
NOTE Confidence: 0.819620173809524  
00:01:39.560 --> 00:01:42.195 single agent and in combination  
NOTE Confidence: 0.819620173809524  
00:01:42.195 --> 00:01:44.830 and ultimately we'll review a  
NOTE Confidence: 0.819620173809524  
00:01:44.924 --> 00:01:47.520 new model for prognostication.  
NOTE Confidence: 0.819620173809524

00:01:47.520 --> 00:01:49.602 So the first abstract I've selected  
NOTE Confidence: 0.819620173809524

00:01:49.602 --> 00:01:52.486 is the long term follow-up of an  
NOTE Confidence: 0.819620173809524

00:01:52.486 --> 00:01:54.382 international randomized phase three  
NOTE Confidence: 0.819620173809524

00:01:54.382 --> 00:01:57.283 study of rituximab versus watching weight  
NOTE Confidence: 0.819620173809524

00:01:57.283 --> 00:01:59.623 approach in patient with asymptomatic  
NOTE Confidence: 0.819620173809524

00:01:59.623 --> 00:02:02.066 low tumor burden follicular lymphoma.  
NOTE Confidence: 0.819620173809524

00:02:02.066 --> 00:02:05.078 Our current approach in these patients  
NOTE Confidence: 0.819620173809524

00:02:05.078 --> 00:02:07.088 population is watch and wait based  
NOTE Confidence: 0.819620173809524

00:02:07.088 --> 00:02:09.056 primarily on data on the Prairie  
NOTE Confidence: 0.819620173809524

00:02:09.056 --> 00:02:11.182 taxicab area that teach didn't show  
NOTE Confidence: 0.819620173809524

00:02:11.182 --> 00:02:12.977 any benefit in early treatment.  
NOTE Confidence: 0.819620173809524

00:02:12.980 --> 00:02:15.265 This study earlier analysis led  
NOTE Confidence: 0.819620173809524

00:02:15.265 --> 00:02:17.550 to the approval of rituximab.  
NOTE Confidence: 0.819620173809524

00:02:17.550 --> 00:02:17.963 Connection.  
NOTE Confidence: 0.819620173809524

00:02:17.963 --> 00:02:20.441 In this patient population in the  
NOTE Confidence: 0.819620173809524

00:02:20.441 --> 00:02:23.898 UK and then here is a presented the

NOTE Confidence: 0.819620173809524

00:02:23.898 --> 00:02:25.610 long-term follow-up analysis with

NOTE Confidence: 0.819620173809524

00:02:25.610 --> 00:02:28.534 a median follow-up of 12.6 years.

NOTE Confidence: 0.819620173809524

00:02:28.534 --> 00:02:32.710 Umm, here's the schema of the uh trial.

NOTE Confidence: 0.819620173809524

00:02:32.710 --> 00:02:36.405 Uh patients have 8018 year old,

NOTE Confidence: 0.819620173809524

00:02:36.405 --> 00:02:38.820 years older within three months of the

NOTE Confidence: 0.819620173809524

00:02:38.886 --> 00:02:41.382 diagnosis with the Grade 138 follicular

NOTE Confidence: 0.819620173809524

00:02:41.382 --> 00:02:44.076 lymphoma and early stage from two to

NOTE Confidence: 0.819620173809524

00:02:44.076 --> 00:02:46.309 four with no organ dysfunction and no

NOTE Confidence: 0.819620173809524

00:02:46.310 --> 00:02:48.848 symptoms and low burden of disease.

NOTE Confidence: 0.819620173809524

00:02:48.850 --> 00:02:51.104 And we'll randomize the to receive it.

NOTE Confidence: 0.819620173809524

00:02:51.110 --> 00:02:53.295 I watch and wait approach

NOTE Confidence: 0.819620173809524

00:02:53.295 --> 00:02:54.169 rituximab induction,

NOTE Confidence: 0.819620173809524

00:02:54.170 --> 00:02:56.786 which consisted in rituximab weekly times

NOTE Confidence: 0.819620173809524

00:02:56.786 --> 00:02:59.739 four or tumor induction plus maintenance.

NOTE Confidence: 0.819620173809524

00:02:59.740 --> 00:03:02.892 For up to two years and the follow-up

NOTE Confidence: 0.819620173809524

00:03:02.892 --> 00:03:05.592 they were monitored with the  
NOTE Confidence: 0.819620173809524

00:03:05.592 --> 00:03:07.736 serial imaging primary endpoint,  
NOTE Confidence: 0.819620173809524

00:03:07.740 --> 00:03:10.398 time to initiation of a new  
NOTE Confidence: 0.819620173809524

00:03:10.398 --> 00:03:12.690 treatment and quality of life.  
NOTE Confidence: 0.819620173809524

00:03:12.690 --> 00:03:15.896 India is a update with a median  
NOTE Confidence: 0.819620173809524

00:03:15.896 --> 00:03:18.152 follow-up duration of 12.7 years.  
NOTE Confidence: 0.819620173809524

00:03:18.152 --> 00:03:20.798 The medium time to initiation of  
NOTE Confidence: 0.819620173809524

00:03:20.798 --> 00:03:23.376 first line treatment was 22.7 years  
NOTE Confidence: 0.819620173809524

00:03:23.376 --> 00:03:25.357 for patients in the watch and wait  
NOTE Confidence: 0.819620173809524

00:03:25.357 --> 00:03:27.372 approach compared to almost 10 years  
NOTE Confidence: 0.819620173809524

00:03:27.372 --> 00:03:29.047 in patients with rituximab induction  
NOTE Confidence: 0.819620173809524

00:03:29.108 --> 00:03:31.348 and not reach the poor patients with  
NOTE Confidence: 0.819620173809524

00:03:31.348 --> 00:03:34.820 rituximab induction plus maintenance.  
NOTE Confidence: 0.819620173809524

00:03:34.820 --> 00:03:38.035 Time from randomization to second  
NOTE Confidence: 0.819620173809524

00:03:38.035 --> 00:03:41.110 treatment was a similarly no  
NOTE Confidence: 0.819620173809524

00:03:41.110 --> 00:03:43.610 difference between the three arms.

NOTE Confidence: 0.939689732

00:03:45.670 --> 00:03:47.390 In terms of overall survival,

NOTE Confidence: 0.939689732

00:03:47.390 --> 00:03:49.539 there was no difference in the overall

NOTE Confidence: 0.939689732

00:03:49.539 --> 00:03:51.089 survival between the true group,

NOTE Confidence: 0.939689732

00:03:51.090 --> 00:03:53.414 the three groups that median overall survival

NOTE Confidence: 0.939689732

00:03:53.414 --> 00:03:55.670 was not reached in the watch and wait,

NOTE Confidence: 0.939689732

00:03:55.670 --> 00:03:59.079 and the taxman maintenance group and was

NOTE Confidence: 0.939689732

00:03:59.079 --> 00:04:03.740 a 17.4 years in the rituximab induction.

NOTE Confidence: 0.939689732

00:04:03.740 --> 00:04:07.494 20% of the 20% of patients that died on

NOTE Confidence: 0.939689732

00:04:07.494 --> 00:04:10.681 average on each arm and 10% of the deaths

NOTE Confidence: 0.939689732

00:04:10.681 --> 00:04:13.214 were attributed to the lymphoma. Um.

NOTE Confidence: 0.939689732

00:04:13.214 --> 00:04:15.278 In terms of high grade transformation

NOTE Confidence: 0.939689732

00:04:15.278 --> 00:04:17.350 and time to 2nd malignancy,

NOTE Confidence: 0.939689732

00:04:17.350 --> 00:04:20.278 again no difference between the three

NOTE Confidence: 0.939689732

00:04:20.278 --> 00:04:23.920 groups with about 20% events of high

NOTE Confidence: 0.939689732

00:04:23.920 --> 00:04:27.110 grade transformation in each arm and 20%

NOTE Confidence: 0.939689732

00:04:27.110 --> 00:04:31.460 of secondary malignancy in each group.  
NOTE Confidence: 0.939689732

00:04:31.460 --> 00:04:33.200 So the other concludes the conclusions  
NOTE Confidence: 0.939689732

00:04:33.200 --> 00:04:35.440 that are are that earlier taxing up  
NOTE Confidence: 0.939689732

00:04:35.440 --> 00:04:37.492 treatment should be considered a standard  
NOTE Confidence: 0.939689732

00:04:37.492 --> 00:04:39.812 option in patient with low turnover  
NOTE Confidence: 0.939689732

00:04:39.812 --> 00:04:41.352 than asymptomatic follicular lymphoma.  
NOTE Confidence: 0.939689732

00:04:41.360 --> 00:04:43.824 Given the significant advantage in time to  
NOTE Confidence: 0.939689732

00:04:43.824 --> 00:04:46.205 new treatment and no detrimental effect  
NOTE Confidence: 0.939689732

00:04:46.205 --> 00:04:48.300 on high grade transformation rates,  
NOTE Confidence: 0.939689732

00:04:48.300 --> 00:04:50.712 secondary primary malignancy and  
NOTE Confidence: 0.939689732

00:04:50.712 --> 00:04:52.521 previously reported improvement  
NOTE Confidence: 0.939689732

00:04:52.521 --> 00:04:55.500 in quality of life measures,  
NOTE Confidence: 0.939689732

00:04:55.500 --> 00:04:57.912 is this practice changing?  
NOTE Confidence: 0.939689732

00:04:57.912 --> 00:05:01.864 I think this is a this is a very valuable.  
NOTE Confidence: 0.939689732

00:05:01.870 --> 00:05:04.444 Data set that will provide us a little bit  
NOTE Confidence: 0.939689732

00:05:04.444 --> 00:05:06.872 more flexibility to better individualized



NOTE Confidence: 0.939689732

00:05:06.872 --> 00:05:09.472 treatment based on patients preferences.

NOTE Confidence: 0.939689732

00:05:09.480 --> 00:05:11.136 I find a very,

NOTE Confidence: 0.939689732

00:05:11.136 --> 00:05:14.051 very reassuring that 1/4 of patients in

NOTE Confidence: 0.939689732

00:05:14.051 --> 00:05:17.280 the watch and weight arm at 12.7 years of

NOTE Confidence: 0.939689732

00:05:17.280 --> 00:05:19.180 follow-up never required any treatment.

NOTE Confidence: 0.939689732

00:05:19.180 --> 00:05:21.462 So I think that this trial also

NOTE Confidence: 0.939689732

00:05:21.462 --> 00:05:23.252 reinforces our approach of watching

NOTE Confidence: 0.939689732

00:05:23.252 --> 00:05:25.117 with strategy in these patients,

NOTE Confidence: 0.939689732

00:05:25.120 --> 00:05:27.584 but it's also good to know that it's

NOTE Confidence: 0.939689732

00:05:27.584 --> 00:05:29.707 not detrimental to start rituximab in

NOTE Confidence: 0.939689732

00:05:29.707 --> 00:05:31.873 those patients who for life preference.

NOTE Confidence: 0.939689732

00:05:31.880 --> 00:05:33.920 Decide to be more uncontrolled

NOTE Confidence: 0.939689732

00:05:33.920 --> 00:05:35.144 of their disease.

NOTE Confidence: 0.939689732

00:05:35.150 --> 00:05:37.364 2nd abstract I've selected is A5

NOTE Confidence: 0.939689732

00:05:37.364 --> 00:05:39.765 year overall five year results and

NOTE Confidence: 0.939689732

00:05:39.765 --> 00:05:42.339 overall survival update from the phase  
NOTE Confidence: 0.939689732

00:05:42.339 --> 00:05:44.777 three augment trial Lenalidomide plus  
NOTE Confidence: 0.939689732

00:05:44.777 --> 00:05:47.292 rituximab versus rituximab plus placebo  
NOTE Confidence: 0.939689732

00:05:47.292 --> 00:05:49.854 in patients with relapsed refractory  
NOTE Confidence: 0.939689732

00:05:49.854 --> 00:05:51.926 indolent and Hodgkin lymphoma.  
NOTE Confidence: 0.939689732

00:05:51.930 --> 00:05:55.461 As we all know the AUGMENT study the  
NOTE Confidence: 0.939689732

00:05:55.461 --> 00:05:57.516 R square the demonstrated superior  
NOTE Confidence: 0.939689732

00:05:57.516 --> 00:05:59.644 efficacy compared to rituximab placebo  
NOTE Confidence: 0.939689732

00:05:59.644 --> 00:06:01.759 in patients with relapsed refractory  
NOTE Confidence: 0.939689732

00:06:01.759 --> 00:06:03.832 and non Hodgkin's lymphoma leading  
NOTE Confidence: 0.939689732

00:06:03.832 --> 00:06:05.116 to the approval of.  
NOTE Confidence: 0.939689732

00:06:05.120 --> 00:06:06.852 These combination in previously  
NOTE Confidence: 0.939689732

00:06:06.852 --> 00:06:09.017 treated follicular and marginal zone  
NOTE Confidence: 0.939689732

00:06:09.017 --> 00:06:10.855 lymphoma when the initial analysis  
NOTE Confidence: 0.939689732

00:06:10.855 --> 00:06:13.143 was published in 2019.  
NOTE Confidence: 0.939689732

00:06:13.143 --> 00:06:17.510 Just reminding the schema of the

NOTE Confidence: 0.939689732

00:06:17.510 --> 00:06:20.240 trial patient that with the follicular

NOTE Confidence: 0.939689732

00:06:20.330 --> 00:06:22.998 lymphoma grade 123A or marginal zone

NOTE Confidence: 0.939689732

00:06:22.998 --> 00:06:25.290 lymphoma that received one prior line

NOTE Confidence: 0.939689732

00:06:25.363 --> 00:06:27.913 of systemic treatment and documented

NOTE Confidence: 0.939689732

00:06:27.913 --> 00:06:29.963 relapse refractory disease but

NOTE Confidence: 0.939689732

00:06:29.963 --> 00:06:32.528 not refractory to rituximab where

NOTE Confidence: 0.939689732

00:06:32.528 --> 00:06:35.130 stratified and randomized to learn.

NOTE Confidence: 0.939689732

00:06:35.130 --> 00:06:38.050 Metaxa amab as we as it is currently

NOTE Confidence: 0.939689732

00:06:38.050 --> 00:06:40.106 approved for with the Lenalidomide

NOTE Confidence: 0.939689732

00:06:40.106 --> 00:06:43.025 for one full year of treatment and

NOTE Confidence: 0.939689732

00:06:43.102 --> 00:06:45.840 rituximab given during the first five cycles,

NOTE Confidence: 0.939689732

00:06:45.840 --> 00:06:49.188 it's only for the 1st 5 cycles and the

NOTE Confidence: 0.939689732

00:06:49.188 --> 00:06:51.740 rituximab placebo was given similarly

NOTE Confidence: 0.939689732

00:06:51.740 --> 00:06:55.590 primary endpoint being PFS secondary

NOTE Confidence: 0.939689732

00:06:55.590 --> 00:06:58.670 endpoints including overall survival.

NOTE Confidence: 0.939689732

00:06:58.670 --> 00:07:01.303 And we,  
NOTE Confidence: 0.939689732

00:07:01.303 --> 00:07:01.796 uh,  
NOTE Confidence: 0.939689732

00:07:01.796 --> 00:07:03.768 with the additional follow-up  
NOTE Confidence: 0.939689732

00:07:03.768 --> 00:07:06.946 provided with this update at a median  
NOTE Confidence: 0.939689732

00:07:06.946 --> 00:07:08.970 follow-up of 65.7 months,  
NOTE Confidence: 0.939689732

00:07:08.970 --> 00:07:12.780 median PFS continued to favor the  
NOTE Confidence: 0.939689732

00:07:12.780 --> 00:07:16.235 R Square group 27.6 months versus  
NOTE Confidence: 0.939689732

00:07:16.235 --> 00:07:19.205 14.3 months in year placebo group  
NOTE Confidence: 0.939689732

00:07:19.210 --> 00:07:21.646 time to the next lymphoma treatment,  
NOTE Confidence: 0.939689732

00:07:21.650 --> 00:07:24.500 which is a more subjective kind  
NOTE Confidence: 0.939689732

00:07:24.500 --> 00:07:26.400 of measure because time  
NOTE Confidence: 0.817100010666667

00:07:26.495 --> 00:07:29.090 to initiation in 320 lymphoma.  
NOTE Confidence: 0.817100010666667

00:07:29.090 --> 00:07:32.906 Is not as a standardized um was continued  
NOTE Confidence: 0.817100010666667

00:07:32.906 --> 00:07:36.570 to favor the R square 73.1 months  
NOTE Confidence: 0.817100010666667

00:07:36.570 --> 00:07:39.320 versus 31.8 months for our placebo.  
NOTE Confidence: 0.817100010666667

00:07:39.320 --> 00:07:42.302 And with fewer patients in the R

NOTE Confidence: 0.817100010666667

00:07:42.302 --> 00:07:44.900 square arm receiving more than one

NOTE Confidence: 0.817100010666667

00:07:44.900 --> 00:07:46.660 subsequent lines of treatment.

NOTE Confidence: 0.817100010666667

00:07:46.660 --> 00:07:49.036 And I think this was the most important,

NOTE Confidence: 0.817100010666667

00:07:49.040 --> 00:07:52.388 the most relevant data that with

NOTE Confidence: 0.817100010666667

00:07:52.388 --> 00:07:55.035 the overall survival analysis with

NOTE Confidence: 0.817100010666667

00:07:55.035 --> 00:07:56.695 this median follow-up extension

NOTE Confidence: 0.817100010666667

00:07:56.695 --> 00:07:59.470 and the two curves have remained.

NOTE Confidence: 0.817100010666667

00:07:59.470 --> 00:08:00.631 Continues to separate.

NOTE Confidence: 0.817100010666667

00:08:00.631 --> 00:08:02.566 Although the median overall survival

NOTE Confidence: 0.817100010666667

00:08:02.566 --> 00:08:04.667 was not reached in either arm,

NOTE Confidence: 0.817100010666667

00:08:04.670 --> 00:08:07.134 there was an improvement in the overall

NOTE Confidence: 0.817100010666667

00:08:07.134 --> 00:08:09.543 survival and the R square compared to

NOTE Confidence: 0.817100010666667

00:08:09.543 --> 00:08:12.772 the R placebo hazard ratio was 0.59 and

NOTE Confidence: 0.817100010666667

00:08:12.772 --> 00:08:15.376 P significantly statistically significant.

NOTE Confidence: 0.817100010666667

00:08:15.380 --> 00:08:17.100 Um.

NOTE Confidence: 0.817100010666667

00:08:17.100 --> 00:08:19.740 And there were no new treatment  
NOTE Confidence: 0.817100010666667

00:08:19.740 --> 00:08:22.540 emergent is reported in this update.  
NOTE Confidence: 0.817100010666667

00:08:22.540 --> 00:08:24.295 This work come came from  
NOTE Confidence: 0.817100010666667

00:08:24.295 --> 00:08:25.348 the original analysis.  
NOTE Confidence: 0.817100010666667

00:08:25.350 --> 00:08:27.684 So not surprisingly there were more  
NOTE Confidence: 0.817100010666667

00:08:27.684 --> 00:08:30.595 toxicity on the R square group compared  
NOTE Confidence: 0.817100010666667

00:08:30.595 --> 00:08:33.577 to the R placebo and especially with  
NOTE Confidence: 0.817100010666667

00:08:33.652 --> 00:08:36.147 the most common being neutropenia.  
NOTE Confidence: 0.817100010666667

00:08:36.150 --> 00:08:37.360 But in the long term,  
NOTE Confidence: 0.817100010666667

00:08:37.360 --> 00:08:39.940 there was no signal that was  
NOTE Confidence: 0.817100010666667

00:08:39.940 --> 00:08:43.297 worrisome for an increase in the risk  
NOTE Confidence: 0.817100010666667

00:08:43.297 --> 00:08:45.369 of secondary primary malignancies  
NOTE Confidence: 0.817100010666667

00:08:45.369 --> 00:08:47.720 due to Lenalidomide exposure.  
NOTE Confidence: 0.817100010666667

00:08:47.720 --> 00:08:48.935 Or histologic transformation.  
NOTE Confidence: 0.817100010666667

00:08:48.935 --> 00:08:51.365 So I think that these updated  
NOTE Confidence: 0.817100010666667

00:08:51.365 --> 00:08:53.612 result further support the use of

NOTE Confidence: 0.817100010666667

00:08:53.612 --> 00:08:55.392 this combination in the relapse

NOTE Confidence: 0.817100010666667

00:08:55.454 --> 00:08:56.620 refractory setting.

NOTE Confidence: 0.90503716

00:08:58.640 --> 00:09:03.405 Moving forward, I'd like to review data on

NOTE Confidence: 0.90503716

00:09:03.405 --> 00:09:06.990 the city 20 CD 3 by specific antibodies.

NOTE Confidence: 0.90503716

00:09:06.990 --> 00:09:09.982 This was a very big and very popular

NOTE Confidence: 0.90503716

00:09:09.982 --> 00:09:12.267 topic attitude this year ASH meeting

NOTE Confidence: 0.90503716

00:09:12.267 --> 00:09:14.910 this antibody as we all know binds

NOTE Confidence: 0.90503716

00:09:14.910 --> 00:09:18.014 CD20 and malignant cell CD3 on T cell

NOTE Confidence: 0.90503716

00:09:18.014 --> 00:09:20.690 eliciting T cell mediated toxicity.

NOTE Confidence: 0.90503716

00:09:20.690 --> 00:09:24.170 We will review here the efficacy and safety

NOTE Confidence: 0.90503716

00:09:24.170 --> 00:09:27.930 data on Mozilla on other next AMAB and.

NOTE Confidence: 0.90503716

00:09:27.930 --> 00:09:29.834 The combination of equipment

NOTE Confidence: 0.90503716

00:09:29.834 --> 00:09:31.738 that with our square,

NOTE Confidence: 0.90503716

00:09:31.740 --> 00:09:34.148 I just want to highlight here that most

NOTE Confidence: 0.90503716

00:09:34.150 --> 00:09:36.950 mob after the this data were presented at

NOTE Confidence: 0.90503716

00:09:36.950 --> 00:09:39.939 the ASH meeting very earlier this year.

NOTE Confidence: 0.90503716

00:09:39.940 --> 00:09:42.460 I received accelerated approval for

NOTE Confidence: 0.90503716

00:09:42.460 --> 00:09:44.980 follicular lymphoma would receive at

NOTE Confidence: 0.90503716

00:09:45.056 --> 00:09:47.480 least two prior lines of treatment

NOTE Confidence: 0.90503716

00:09:47.480 --> 00:09:50.560 including an anti CD20 antibody and

NOTE Confidence: 0.90503716

00:09:50.560 --> 00:09:53.620 an alkylating agent or the next Amada.

NOTE Confidence: 0.90503716

00:09:53.620 --> 00:09:55.120 Also very promising results we're

NOTE Confidence: 0.90503716

00:09:55.120 --> 00:09:56.928 going to review as being granted

NOTE Confidence: 0.90503716

00:09:56.928 --> 00:09:58.640 fast track designation by the FDA.

NOTE Confidence: 0.90503716

00:09:58.640 --> 00:10:01.220 Or fully comic drama.

NOTE Confidence: 0.90503716

00:10:01.220 --> 00:10:04.436 So here the update on uh,

NOTE Confidence: 0.90503716

00:10:04.440 --> 00:10:06.732 the people that were phase two

NOTE Confidence: 0.90503716

00:10:06.732 --> 00:10:09.291 study on monotherapy in patients

NOTE Confidence: 0.90503716

00:10:09.291 --> 00:10:11.679 with relapsed refractory lymphoma.

NOTE Confidence: 0.90503716

00:10:11.680 --> 00:10:13.208 Key inclusion criteria included

NOTE Confidence: 0.90503716

00:10:13.208 --> 00:10:14.736 patients with follicular lymphoma



NOTE Confidence: 0.90503716

00:10:14.736 --> 00:10:17.115 grade one to three a with a good

NOTE Confidence: 0.90503716

00:10:17.115 --> 00:10:18.495 performance status with more than

NOTE Confidence: 0.90503716

00:10:18.495 --> 00:10:19.940 two prior lines of treatment.

NOTE Confidence: 0.90503716

00:10:19.940 --> 00:10:23.492 The by specific antibody was given

NOTE Confidence: 0.90503716

00:10:23.492 --> 00:10:26.401 intravenously with a step up

NOTE Confidence: 0.90503716

00:10:26.401 --> 00:10:29.496 dosing in cycle one that is usually

NOTE Confidence: 0.90503716

00:10:29.496 --> 00:10:31.304 a strategy to mitigate.

NOTE Confidence: 0.90503716

00:10:31.310 --> 00:10:34.244 The risk of CRS that that is unique to

NOTE Confidence: 0.90503716

00:10:34.244 --> 00:10:37.291 this group of drugs and then subsequent

NOTE Confidence: 0.90503716

00:10:37.291 --> 00:10:41.810 to the step up dosing was a given day

NOTE Confidence: 0.90503716

00:10:41.810 --> 00:10:44.629 one of every cycle 60 milligrams with

NOTE Confidence: 0.90503716

00:10:44.629 --> 00:10:47.191 cycle two down to 30 with cycle 3

NOTE Confidence: 0.90503716

00:10:47.191 --> 00:10:49.326 on it was a fixed duration treatment.

NOTE Confidence: 0.90503716

00:10:49.330 --> 00:10:51.546 People achieving patients achieving

NOTE Confidence: 0.90503716

00:10:51.546 --> 00:10:54.870 CR after 8 cycles stopped treatment

NOTE Confidence: 0.90503716

00:10:54.953 --> 00:10:57.527 and we're allowed to be retreated  
NOTE Confidence: 0.90503716

00:10:57.527 --> 00:10:59.456 should the recurrence patient  
NOTE Confidence: 0.90503716

00:10:59.456 --> 00:11:01.588 achieving a stable disease.  
NOTE Confidence: 0.90503716

00:11:01.590 --> 00:11:03.195 Was a partial remission continued  
NOTE Confidence: 0.90503716

00:11:03.195 --> 00:11:05.260 on the treatment for 17 cycles.  
NOTE Confidence: 0.90503716

00:11:05.260 --> 00:11:07.695 There were no mandatory hospitalization  
NOTE Confidence: 0.90503716

00:11:07.695 --> 00:11:10.675 and the study made its primary  
NOTE Confidence: 0.90503716

00:11:10.675 --> 00:11:13.435 endpoint of efficacy at the prior  
NOTE Confidence: 0.90503716

00:11:13.440 --> 00:11:16.050 published initial analysis with a  
NOTE Confidence: 0.90503716

00:11:16.050 --> 00:11:19.712 rate of 60% in patients that compared  
NOTE Confidence: 0.90503716

00:11:19.712 --> 00:11:22.077 to 14% of historical control.  
NOTE Confidence: 0.90503716

00:11:22.077 --> 00:11:25.728 And here it was provided an updated efficacy  
NOTE Confidence: 0.90503716

00:11:25.728 --> 00:11:29.235 and safety analysis with a longer follow-up,  
NOTE Confidence: 0.90503716

00:11:29.240 --> 00:11:32.635 10 months longer than the original analysis.  
NOTE Confidence: 0.90503716

00:11:32.640 --> 00:11:33.555 Baseline characteristics I  
NOTE Confidence: 0.90503716

00:11:33.555 --> 00:11:35.080 just want to highlight here,

NOTE Confidence: 0.90503716

00:11:35.080 --> 00:11:36.271 these were very,

NOTE Confidence: 0.90503716

00:11:36.271 --> 00:11:37.859 very heavily pretreated patients

NOTE Confidence: 0.90503716

00:11:37.859 --> 00:11:40.422 and patients up to the age of 90

NOTE Confidence: 0.90503716

00:11:40.422 --> 00:11:42.130 were included in the study and

NOTE Confidence: 0.90503716

00:11:42.130 --> 00:11:44.104 there were a lot of significant

NOTE Confidence: 0.90503716

00:11:44.104 --> 00:11:46.159 proportion of what we call PD-24,

NOTE Confidence: 0.90503716

00:11:46.159 --> 00:11:49.116 which are very, very high risk patient

NOTE Confidence: 0.90503716

00:11:49.116 --> 00:11:51.960 that usually have a worse outcome.

NOTE Confidence: 0.90503716

00:11:51.960 --> 00:11:52.530 Um,

NOTE Confidence: 0.90503716

00:11:52.530 --> 00:11:53.670 these analysis,

NOTE Confidence: 0.90503716

00:11:53.670 --> 00:11:57.090 there was no difference in the

NOTE Confidence: 0.90503716

00:11:57.090 --> 00:11:59.968 reported efficacy compared to the prior

NOTE Confidence: 0.90503716

00:11:59.968 --> 00:12:02.110 analysis with an overall response rate

NOTE Confidence: 0.90503716

00:12:02.175 --> 00:12:04.978 of almost 80% and a CR rate of 60%.

NOTE Confidence: 0.90503716

00:12:04.980 --> 00:12:07.890 Very quick time to 1st respond 1.4

NOTE Confidence: 0.90503716

00:12:07.890 --> 00:12:10.200 months and three months for the time

NOTE Confidence: 0.90503716

00:12:10.200 --> 00:12:13.341 to the CR I think was what is more

NOTE Confidence: 0.90503716

00:12:13.341 --> 00:12:15.255 meaningful about this update is

NOTE Confidence: 0.90503716

00:12:15.255 --> 00:12:17.679 that the duration of these responses

NOTE Confidence: 0.90503716

00:12:17.680 --> 00:12:19.744 and the benefit that appeared to

NOTE Confidence: 0.90503716

00:12:19.744 --> 00:12:21.120 be very impressive especially

NOTE Confidence: 0.90503716

00:12:21.179 --> 00:12:22.789 when compared to the benefit.

NOTE Confidence: 0.90503716

00:12:22.790 --> 00:12:25.485 Achieved with the prior line of treatment

NOTE Confidence: 0.90503716

00:12:25.485 --> 00:12:27.323 before Mozilla Tasm having these

NOTE Confidence: 0.90503716

00:12:27.323 --> 00:12:29.795 patient as we see here the blue line

NOTE Confidence: 0.692425145833333

00:12:29.863 --> 00:12:32.068 is most inotuzumab prior to your 20s

NOTE Confidence: 0.692425145833333

00:12:32.068 --> 00:12:34.664 in red median duration of complete

NOTE Confidence: 0.692425145833333

00:12:34.664 --> 00:12:37.404 response not reached for monotheism

NOTE Confidence: 0.692425145833333

00:12:37.404 --> 00:12:41.225 15 months for prior treatment and

NOTE Confidence: 0.692425145833333

00:12:41.225 --> 00:12:44.490 PFS similarly favoring like was

NOTE Confidence: 0.692425145833333

00:12:44.490 --> 00:12:46.583 was 24 months compared to 12 months

NOTE Confidence: 0.692425145833333  
00:12:46.583 --> 00:12:48.698 for a prior line of treatment.  
NOTE Confidence: 0.692425145833333  
00:12:48.700 --> 00:12:50.988 And I think this is very important in  
NOTE Confidence: 0.692425145833333  
00:12:50.988 --> 00:12:52.909 the because breaks as sort of the.  
NOTE Confidence: 0.692425145833333  
00:12:52.910 --> 00:12:55.490 Vicious cycle in patients with particular  
NOTE Confidence: 0.692425145833333  
00:12:55.490 --> 00:12:57.615 lymphoma with subsequent lines of  
NOTE Confidence: 0.692425145833333  
00:12:57.615 --> 00:12:59.315 treatment usually and the duration  
NOTE Confidence: 0.692425145833333  
00:12:59.315 --> 00:13:01.759 of response is half of the prior one.  
NOTE Confidence: 0.692425145833333  
00:13:01.760 --> 00:13:04.060 In terms of safety profile,  
NOTE Confidence: 0.692425145833333  
00:13:04.060 --> 00:13:08.060 there was not an update on the ages  
NOTE Confidence: 0.692425145833333  
00:13:08.060 --> 00:13:09.890 reported in the original analysis  
NOTE Confidence: 0.692425145833333  
00:13:09.890 --> 00:13:12.401 and most of the adverse event not  
NOTE Confidence: 0.692425145833333  
00:13:12.401 --> 00:13:14.865 related to CRS where Grade 3 and grade  
NOTE Confidence: 0.692425145833333  
00:13:14.932 --> 00:13:16.804 four were essentially neutropenia  
NOTE Confidence: 0.692425145833333  
00:13:16.804 --> 00:13:18.676 and hypophosphatemia which seemed  
NOTE Confidence: 0.692425145833333  
00:13:18.676 --> 00:13:21.268 to be appear to be manageable.  
NOTE Confidence: 0.692425145833333

00:13:21.268 --> 00:13:23.740 And also in terms of CRS,  
NOTE Confidence: 0.692425145833333  
00:13:23.740 --> 00:13:25.798 most of the CRS were predictable  
NOTE Confidence: 0.692425145833333  
00:13:25.798 --> 00:13:28.232 after the first dose and after the  
NOTE Confidence: 0.692425145833333  
00:13:28.232 --> 00:13:30.218 first full dose of the antibody,  
NOTE Confidence: 0.692425145833333  
00:13:30.220 --> 00:13:31.900 mostly grade one and grade.  
NOTE Confidence: 0.692425145833333  
00:13:31.900 --> 00:13:33.718 That was on a grade three and a grade  
NOTE Confidence: 0.692425145833333  
00:13:33.718 --> 00:13:35.469 four was in a patient that apparently  
NOTE Confidence: 0.692425145833333  
00:13:35.469 --> 00:13:37.074 had a leukemic form of follicular  
NOTE Confidence: 0.692425145833333  
00:13:37.074 --> 00:13:39.020 lymphoma with a very high white count.  
NOTE Confidence: 0.692425145833333  
00:13:39.020 --> 00:13:41.274 So had a really high risk features.  
NOTE Confidence: 0.692425145833333  
00:13:41.280 --> 00:13:43.555 And again this is I think practice  
NOTE Confidence: 0.692425145833333  
00:13:43.555 --> 00:13:45.595 changing after the FDA approved this  
NOTE Confidence: 0.692425145833333  
00:13:45.595 --> 00:13:47.599 drug in the third line setting,  
NOTE Confidence: 0.692425145833333  
00:13:47.600 --> 00:13:49.968 we have now a new option and it's  
NOTE Confidence: 0.692425145833333  
00:13:49.968 --> 00:13:51.685 very exciting and it's probably  
NOTE Confidence: 0.692425145833333  
00:13:51.685 --> 00:13:53.803 going to be in direct competition

NOTE Confidence: 0.692425145833333

00:13:53.803 --> 00:13:56.104 with car T cell in this space.

NOTE Confidence: 0.692425145833333

00:13:56.104 --> 00:13:59.030 I just want to highlight here a

NOTE Confidence: 0.692425145833333

00:13:59.130 --> 00:14:01.528 poster presentation that has.

NOTE Confidence: 0.692425145833333

00:14:01.528 --> 00:14:04.222 If in time happens when a drug shows

NOTE Confidence: 0.692425145833333

00:14:04.222 --> 00:14:06.334 such an amazing activity in patients

NOTE Confidence: 0.692425145833333

00:14:06.334 --> 00:14:08.261 that are heavily pretreated and

NOTE Confidence: 0.692425145833333

00:14:08.261 --> 00:14:10.266 in subsequent line of treatment,

NOTE Confidence: 0.692425145833333

00:14:10.270 --> 00:14:13.091 it is attested earlier in the course

NOTE Confidence: 0.692425145833333

00:14:13.091 --> 00:14:15.906 of the treatment and in combination

NOTE Confidence: 0.692425145833333

00:14:15.906 --> 00:14:17.946 with the approved treatment.

NOTE Confidence: 0.692425145833333

00:14:17.950 --> 00:14:20.170 And we have currently opened here

NOTE Confidence: 0.692425145833333

00:14:20.170 --> 00:14:23.094 at Yale under the lead of Doctor

NOTE Confidence: 0.692425145833333

00:14:23.094 --> 00:14:25.502 Huntington clinical trial here's in

NOTE Confidence: 0.692425145833333

00:14:25.502 --> 00:14:27.454 combination in collaboration with

NOTE Confidence: 0.692425145833333

00:14:27.454 --> 00:14:28.430 Brown University.

NOTE Confidence: 0.692425145833333

00:14:28.430 --> 00:14:31.895 This is a map with the land.  
NOTE Confidence: 0.692425145833333

00:14:31.900 --> 00:14:33.725 Augmentation as first line therapy  
NOTE Confidence: 0.692425145833333

00:14:33.725 --> 00:14:35.550 for follicular and marginal zone  
NOTE Confidence: 0.692425145833333

00:14:35.611 --> 00:14:37.546 lymphoma in these clinical trial  
NOTE Confidence: 0.692425145833333

00:14:37.546 --> 00:14:39.094 patients with untreated follicular  
NOTE Confidence: 0.692425145833333

00:14:39.094 --> 00:14:41.472 and marginal zone lymphoma in need of  
NOTE Confidence: 0.692425145833333

00:14:41.472 --> 00:14:44.352 treatment will be treated with Mozilla.  
NOTE Confidence: 0.692425145833333

00:14:44.352 --> 00:14:47.110 As we reviewed previously.  
NOTE Confidence: 0.692425145833333

00:14:47.110 --> 00:14:49.700 The same schedule is going to be  
NOTE Confidence: 0.692425145833333

00:14:49.700 --> 00:14:51.335 given though subcutaneously after  
NOTE Confidence: 0.692425145833333

00:14:51.335 --> 00:14:53.825 four cycle patients in CR will  
NOTE Confidence: 0.692425145833333

00:14:53.825 --> 00:14:56.108 continue for a total of eight  
NOTE Confidence: 0.692425145833333

00:14:56.108 --> 00:14:57.838 cycle patient not achieving CR.  
NOTE Confidence: 0.692425145833333

00:14:57.840 --> 00:14:59.808 So with the partial response of  
NOTE Confidence: 0.692425145833333

00:14:59.808 --> 00:15:01.979 stable disease will go on receiving.  
NOTE Confidence: 0.692425145833333

00:15:01.980 --> 00:15:03.975 Augmentation with Lenalidomide 4 to



NOTE Confidence: 0.692425145833333  
00:15:03.975 --> 00:15:06.763 complete its cycle and then there is  
NOTE Confidence: 0.692425145833333  
00:15:06.763 --> 00:15:08.568 provision for an extended documentation  
NOTE Confidence: 0.692425145833333  
00:15:08.568 --> 00:15:11.370 if no CR is achieved after cycle 8.  
NOTE Confidence: 0.692425145833333  
00:15:11.370 --> 00:15:13.110 Primary endpoints of the studies  
NOTE Confidence: 0.692425145833333  
00:15:13.110 --> 00:15:14.502 are overall response rate,  
NOTE Confidence: 0.692425145833333  
00:15:14.510 --> 00:15:17.030 CR rate and PFS and there are  
NOTE Confidence: 0.692425145833333  
00:15:17.030 --> 00:15:18.110 correlative studies looking  
NOTE Confidence: 0.692425145833333  
00:15:18.175 --> 00:15:20.067 at the tumor microenvironment,  
NOTE Confidence: 0.692425145833333  
00:15:20.070 --> 00:15:26.110 CD, circulating DNA and MRT.  
NOTE Confidence: 0.692425145833333  
00:15:26.110 --> 00:15:26.838 Moving forward,  
NOTE Confidence: 0.692425145833333  
00:15:26.838 --> 00:15:29.022 the other very promising by specific  
NOTE Confidence: 0.692425145833333  
00:15:29.022 --> 00:15:31.092 antibody that was presented at the  
NOTE Confidence: 0.692425145833333  
00:15:31.092 --> 00:15:32.692 ASH meeting in follicular lymphoma  
NOTE Confidence: 0.692425145833333  
00:15:32.692 --> 00:15:35.039 is other next amab and be very quick  
NOTE Confidence: 0.692425145833333  
00:15:35.039 --> 00:15:36.718 here because it's essentially the  
NOTE Confidence: 0.692425145833333

00:15:36.718 --> 00:15:39.616 data are similar to the one that  
NOTE Confidence: 0.692425145833333

00:15:39.616 --> 00:15:42.490 we have reviewed with most about  
NOTE Confidence: 0.692425145833333

00:15:42.490 --> 00:15:45.490 though the follow-up was much shorter  
NOTE Confidence: 0.825341224

00:15:45.490 --> 00:15:48.352 and it is given with a step up dosing  
NOTE Confidence: 0.825341224

00:15:48.352 --> 00:15:51.349 that was changed in the course of the  
NOTE Confidence: 0.825341224

00:15:51.349 --> 00:15:53.816 study to further mitigate the risk of  
NOTE Confidence: 0.825341224

00:15:53.816 --> 00:15:56.915 a Sears and so it was a little bit.  
NOTE Confidence: 0.825341224

00:15:56.915 --> 00:16:00.070 Or day one and day two they get  
NOTE Confidence: 0.825341224

00:16:00.070 --> 00:16:02.709 91516 of cycle 1 escalated to the  
NOTE Confidence: 0.825341224

00:16:02.709 --> 00:16:04.629 full dose Hollywood cycle two.  
NOTE Confidence: 0.825341224

00:16:04.630 --> 00:16:07.157 And the way that these by specific  
NOTE Confidence: 0.825341224

00:16:07.157 --> 00:16:09.976 antibody was given as a sort of  
NOTE Confidence: 0.825341224

00:16:09.976 --> 00:16:11.224 maintenance continuous treatment  
NOTE Confidence: 0.825341224

00:16:11.224 --> 00:16:13.904 every two weeks of again here we  
NOTE Confidence: 0.825341224

00:16:13.904 --> 00:16:15.950 see similar response rate than we  
NOTE Confidence: 0.825341224

00:16:15.950 --> 00:16:19.990 have seen with most of a very high

NOTE Confidence: 0.825341224

00:16:19.990 --> 00:16:23.350 overall response rate over 80% and the

NOTE Confidence: 0.825341224

00:16:23.350 --> 00:16:25.722 complete response rate 75% medium.

NOTE Confidence: 0.825341224

00:16:25.722 --> 00:16:28.518 Uh opportunity to follow up has

NOTE Confidence: 0.825341224

00:16:28.518 --> 00:16:30.250 been uh 2022.4 months.

NOTE Confidence: 0.825341224

00:16:30.250 --> 00:16:32.650 And in terms of safety profile,

NOTE Confidence: 0.825341224

00:16:32.650 --> 00:16:37.174 again similar to mob neutropenia

NOTE Confidence: 0.825341224

00:16:37.174 --> 00:16:39.284 was a big adverse event.

NOTE Confidence: 0.825341224

00:16:39.290 --> 00:16:42.377 Besides the CRS and CRS risk were

NOTE Confidence: 0.825341224

00:16:42.377 --> 00:16:44.850 mostly grade one and Grade 2,

NOTE Confidence: 0.825341224

00:16:44.850 --> 00:16:46.546 especially after the optimization

NOTE Confidence: 0.825341224

00:16:46.546 --> 00:16:48.666 of the step up regimen,

NOTE Confidence: 0.825341224

00:16:48.670 --> 00:16:51.466 Grade 3 became much less frequent

NOTE Confidence: 0.825341224

00:16:51.466 --> 00:16:54.436 and just to remind what is a

NOTE Confidence: 0.825341224

00:16:54.436 --> 00:16:56.464 big deal at Grade 3 CRS.

NOTE Confidence: 0.825341224

00:16:56.470 --> 00:16:59.249 Is that with the demand high grade

NOTE Confidence: 0.825341224

00:16:59.249 --> 00:17:01.070 oxygen and vasopressor support?  
NOTE Confidence: 0.849085844285714

00:17:03.480 --> 00:17:06.315 Finally, I'd like to review this study,  
NOTE Confidence: 0.849085844285714

00:17:06.320 --> 00:17:08.044 the subcutaneous combination of  
NOTE Confidence: 0.849085844285714

00:17:08.044 --> 00:17:09.768 ecilizumab with rituximab and  
NOTE Confidence: 0.849085844285714

00:17:09.768 --> 00:17:12.056 Lenalidomide in patients with relapsed  
NOTE Confidence: 0.849085844285714

00:17:12.056 --> 00:17:13.880 or refractory follicular lymphoma.  
NOTE Confidence: 0.849085844285714

00:17:13.880 --> 00:17:16.640 So by specific antibody in combination  
NOTE Confidence: 0.849085844285714

00:17:16.640 --> 00:17:19.163 with an approved chemo immunotherapy  
NOTE Confidence: 0.849085844285714

00:17:19.163 --> 00:17:22.781 and these were patient with follicular  
NOTE Confidence: 0.849085844285714

00:17:22.781 --> 00:17:25.101 lymphoma relapse refractory need  
NOTE Confidence: 0.849085844285714

00:17:25.101 --> 00:17:27.236 for treatment and there were.  
NOTE Confidence: 0.849085844285714

00:17:27.240 --> 00:17:31.060 Included higher risk patient epically  
NOTE Confidence: 0.849085844285714

00:17:31.060 --> 00:17:36.350 was given subcutaneously and for.  
NOTE Confidence: 0.849085844285714

00:17:36.350 --> 00:17:38.600 And was given in combination with  
NOTE Confidence: 0.849085844285714

00:17:38.600 --> 00:17:41.144 rituximab and lend a little while  
NOTE Confidence: 0.849085844285714

00:17:41.144 --> 00:17:43.088 following the AUGMENT schema.

NOTE Confidence: 0.849085844285714  
00:17:43.090 --> 00:17:45.342 Treatment lasted 2 years.  
NOTE Confidence: 0.849085844285714  
00:17:45.342 --> 00:17:48.157 Primary objective was in safety  
NOTE Confidence: 0.849085844285714  
00:17:48.157 --> 00:17:50.569 and antitumor activity.  
NOTE Confidence: 0.849085844285714  
00:17:50.570 --> 00:17:52.538 Treatment emergent adverse event  
NOTE Confidence: 0.849085844285714  
00:17:52.538 --> 00:17:56.220 as expected based on the R square  
NOTE Confidence: 0.849085844285714  
00:17:56.220 --> 00:17:59.085 toxicity profile and I think the study  
NOTE Confidence: 0.849085844285714  
00:17:59.085 --> 00:18:02.087 was impacted by the fact that it was  
NOTE Confidence: 0.849085844285714  
00:18:02.087 --> 00:18:04.327 conducting during the COVID-19 pandemic.  
NOTE Confidence: 0.849085844285714  
00:18:04.330 --> 00:18:07.025 With many patients contracting the CD 19,  
NOTE Confidence: 0.849085844285714  
00:18:07.030 --> 00:18:09.214 COVID-19 in less CSS,  
NOTE Confidence: 0.849085844285714  
00:18:09.214 --> 00:18:11.744 the event very minimal,  
NOTE Confidence: 0.849085844285714  
00:18:11.744 --> 00:18:15.329 very encouraging these results and  
NOTE Confidence: 0.849085844285714  
00:18:15.330 --> 00:18:17.528 mostly grade one and grade two no  
NOTE Confidence: 0.849085844285714  
00:18:17.528 --> 00:18:21.188 grade three years was recorded and  
NOTE Confidence: 0.849085844285714  
00:18:21.188 --> 00:18:24.939 overall response rate 95% with a  
NOTE Confidence: 0.849085844285714

00:18:24.939 --> 00:18:27.404 complete metabolic response of 80%.  
NOTE Confidence: 0.849085844285714

00:18:27.410 --> 00:18:30.346 So based on these very exciting  
NOTE Confidence: 0.849085844285714

00:18:30.346 --> 00:18:31.926 results there is currently a  
NOTE Confidence: 0.849085844285714

00:18:31.926 --> 00:18:33.960 phase three trial of subcutaneous.  
NOTE Confidence: 0.849085844285714

00:18:33.960 --> 00:18:35.895 Create the mapping combination with  
NOTE Confidence: 0.849085844285714

00:18:35.895 --> 00:18:39.336 our square uh versus uh R square among  
NOTE Confidence: 0.849085844285714

00:18:39.336 --> 00:18:41.252 patients with relapsed refractory  
NOTE Confidence: 0.849085844285714

00:18:41.252 --> 00:18:43.480 follicular lymphoma that is ongoing.  
NOTE Confidence: 0.849085844285714

00:18:43.480 --> 00:18:46.343 I'd like to close my selection of  
NOTE Confidence: 0.849085844285714

00:18:46.343 --> 00:18:49.048 abstract with uh these abstract  
NOTE Confidence: 0.849085844285714

00:18:49.048 --> 00:18:50.440 on prognostication.  
NOTE Confidence: 0.849085844285714

00:18:50.440 --> 00:18:52.828 This is a very important and  
NOTE Confidence: 0.849085844285714

00:18:52.828 --> 00:18:56.114 area of clinical and met need for  
NOTE Confidence: 0.849085844285714

00:18:56.114 --> 00:18:57.186 follicular lymphoma.  
NOTE Confidence: 0.849085844285714

00:18:57.190 --> 00:18:59.482 We know the patients of particular  
NOTE Confidence: 0.849085844285714

00:18:59.482 --> 00:19:01.726 lymphoma is very terrigenous with the

NOTE Confidence: 0.849085844285714  
00:19:01.726 --> 00:19:03.790 patient doing well on the watch and  
NOTE Confidence: 0.849085844285714  
00:19:03.790 --> 00:19:06.112 wait approach for more than 12 years  
NOTE Confidence: 0.849085844285714  
00:19:06.112 --> 00:19:07.942 and patients instead relapsing with  
NOTE Confidence: 0.849085844285714  
00:19:07.942 --> 00:19:10.150 their disease within 24 months from  
NOTE Confidence: 0.849085844285714  
00:19:10.150 --> 00:19:11.920 initiation of a chemo immunotherapy  
NOTE Confidence: 0.849085844285714  
00:19:11.920 --> 00:19:13.600 and those are really the patients.  
NOTE Confidence: 0.849085844285714  
00:19:13.600 --> 00:19:19.670 That we really need to do more  
NOTE Confidence: 0.849085844285714  
00:19:19.670 --> 00:19:23.225 research and develop new treatment  
NOTE Confidence: 0.849085844285714  
00:19:23.225 --> 00:19:26.255 paradigm for because these are the  
NOTE Confidence: 0.849085844285714  
00:19:26.255 --> 00:19:29.431 patients that have the more challenging  
NOTE Confidence: 0.849085844285714  
00:19:29.431 --> 00:19:32.330 prognosis so in the this study.  
NOTE Confidence: 0.849085844285714  
00:19:32.330 --> 00:19:36.054 And it is presented at new prognostic  
NOTE Confidence: 0.849085844285714  
00:19:36.054 --> 00:19:39.166 model called Flippy 24 and this model  
NOTE Confidence: 0.849085844285714  
00:19:39.166 --> 00:19:41.226 was specifically developed to predict  
NOTE Confidence: 0.849085844285714  
00:19:41.226 --> 00:19:43.403 the risk of disease progression  
NOTE Confidence: 0.849085844285714

00:19:43.403 --> 00:19:45.959 within 24 months from starting the  
NOTE Confidence: 0.849085844285714

00:19:45.959 --> 00:19:48.347 first line of chemo immunotherapy.  
NOTE Confidence: 0.849085844285714

00:19:48.350 --> 00:19:50.870 So we currently we have no current  
NOTE Confidence: 0.849085844285714

00:19:50.870 --> 00:19:53.342 tool to identify these patients and  
NOTE Confidence: 0.849085844285714

00:19:53.342 --> 00:19:55.970 having the ability of identifying these  
NOTE Confidence: 0.849085844285714

00:19:55.970 --> 00:19:58.674 POD 24 patients earlier will help  
NOTE Confidence: 0.849085844285714

00:19:58.674 --> 00:20:01.324 direct clinical trials and novel therapy.  
NOTE Confidence: 0.849085844285714

00:20:01.324 --> 00:20:05.410 So these are flip 24 model uses 5 lineal  
NOTE Confidence: 0.849085844285714

00:20:05.506 --> 00:20:08.950 variable age LDH hemoglobin WBC and  
NOTE Confidence: 0.849085844285714

00:20:08.950 --> 00:20:12.829 beta 2 microglobulin which are very easily.  
NOTE Confidence: 0.849085844285714

00:20:12.830 --> 00:20:15.252 Which are common variables that we have  
NOTE Confidence: 0.849085844285714

00:20:15.252 --> 00:20:17.598 available for all of our patients and  
NOTE Confidence: 0.849085844285714

00:20:17.598 --> 00:20:20.130 it's based on these five linear variables.  
NOTE Confidence: 0.849085844285714

00:20:20.130 --> 00:20:22.402 It divides patient risks.  
NOTE Confidence: 0.849085844285714

00:20:22.402 --> 00:20:25.242 Patients in five risk group,  
NOTE Confidence: 0.849085844285714

00:20:25.250 --> 00:20:27.350 the low Risk group has less than



NOTE Confidence: 0.849085844285714

00:20:27.350 --> 00:20:30.050 10% chances of developing a POD 20

NOTE Confidence: 0.849085844285714

00:20:30.050 --> 00:20:32.562 to to progressive within 24 months

NOTE Confidence: 0.849085844285714

00:20:32.562 --> 00:20:34.637 from the initial treatment versus

NOTE Confidence: 0.849085844285714

00:20:34.637 --> 00:20:37.489 the very high risk has a very high,

NOTE Confidence: 0.849085844285714

00:20:37.490 --> 00:20:41.102 more than 40% chance of progressing

NOTE Confidence: 0.849085844285714

00:20:41.102 --> 00:20:43.546 and therefore I think that.

NOTE Confidence: 0.849085844285714

00:20:43.546 --> 00:20:46.018 This model would provide a good

NOTE Confidence: 0.849085844285714

00:20:46.018 --> 00:20:48.593 platform for future models and

NOTE Confidence: 0.849085844285714

00:20:48.593 --> 00:20:50.612 incorporating maybe other information.

NOTE Confidence: 0.849085844285714

00:20:50.612 --> 00:20:53.042 Tumor total metabolic tumor volume

NOTE Confidence: 0.849085844285714

00:20:53.042 --> 00:20:56.594 seems to be an emerging important

NOTE Confidence: 0.849085844285714

00:20:56.594 --> 00:20:57.940 independent predictors,

NOTE Confidence: 0.849085844285714

00:20:57.940 --> 00:21:00.778 predictors for response especially in Carti.

NOTE Confidence: 0.856813196

00:21:00.780 --> 00:21:02.860 We don't have a lot of data about

NOTE Confidence: 0.856813196

00:21:02.860 --> 00:21:05.357 that in by specific antibodies so far,

NOTE Confidence: 0.856813196

00:21:05.360 --> 00:21:09.520 but I think this was a good start.

NOTE Confidence: 0.856813196

00:21:09.520 --> 00:21:13.178 So in summary, we have reviewed the

NOTE Confidence: 0.856813196

00:21:13.178 --> 00:21:14.972 data that showed that the rituximab

NOTE Confidence: 0.856813196

00:21:14.972 --> 00:21:16.443 induction plus of maintenance plus

NOTE Confidence: 0.856813196

00:21:16.443 --> 00:21:17.818 or minus maintenance appears to

NOTE Confidence: 0.856813196

00:21:17.818 --> 00:21:19.373 be non inferior non detrimental

NOTE Confidence: 0.856813196

00:21:19.373 --> 00:21:21.281 alternative to watch and wait for

NOTE Confidence: 0.856813196

00:21:21.281 --> 00:21:22.872 selected patients with asymptomatic

NOTE Confidence: 0.856813196

00:21:22.872 --> 00:21:25.416 low tumor burden for liquor lymphoma.

NOTE Confidence: 0.856813196

00:21:25.420 --> 00:21:27.856 5 year follow-up of Lenalidomide of

NOTE Confidence: 0.856813196

00:21:27.856 --> 00:21:30.797 Ataxia map continues to show PFS and

NOTE Confidence: 0.856813196

00:21:30.797 --> 00:21:32.862 an overall survival benefit compared

NOTE Confidence: 0.856813196

00:21:32.862 --> 00:21:35.272 to placebo with rituximab CD20CD3

NOTE Confidence: 0.856813196

00:21:35.272 --> 00:21:37.440 bispecific antibody demonstrated durable

NOTE Confidence: 0.856813196

00:21:37.440 --> 00:21:40.150 efficacy with manageable toxicity and.

NOTE Confidence: 0.856813196

00:21:40.150 --> 00:21:41.775 High risk patients with follicular

NOTE Confidence: 0.856813196

00:21:41.775 --> 00:21:43.799 lymphoma and was INOTUZUMAB has now

NOTE Confidence: 0.856813196

00:21:43.799 --> 00:21:45.499 received the accelerated FDA approval

NOTE Confidence: 0.856813196

00:21:45.499 --> 00:21:47.360 in patients with follicular lymphoma.

NOTE Confidence: 0.856813196

00:21:47.360 --> 00:21:48.860 In the third line setting.

NOTE Confidence: 0.856813196

00:21:48.860 --> 00:21:50.810 There are ongoing clinical trials

NOTE Confidence: 0.856813196

00:21:50.810 --> 00:21:52.760 that are evaluating by specific

NOTE Confidence: 0.856813196

00:21:52.827 --> 00:21:54.879 earlier in the lines of treatment

NOTE Confidence: 0.856813196

00:21:54.879 --> 00:21:56.749 and in combination with approved

NOTE Confidence: 0.856813196

00:21:56.749 --> 00:21:58.489 treatments and the identification

NOTE Confidence: 0.856813196

00:21:58.489 --> 00:22:01.570 of diagnosis of PDD 24 patients is a

NOTE Confidence: 0.856813196

00:22:01.570 --> 00:22:03.340 very important clinical unmet need.

NOTE Confidence: 0.856813196

00:22:03.340 --> 00:22:05.788 This new flip 24 model proposed

NOTE Confidence: 0.856813196

00:22:05.788 --> 00:22:08.465 by Mayo Clinic and emerging data

NOTE Confidence: 0.856813196

00:22:08.465 --> 00:22:10.855 on a total metabolic tumor.

NOTE Confidence: 0.856813196

00:22:10.860 --> 00:22:13.635 Burden and hopefully will help

NOTE Confidence: 0.856813196

00:22:13.635 --> 00:22:15.855 us prognosticate better these  
NOTE Confidence: 0.856813196

00:22:15.855 --> 00:22:17.490 subset of patients.  
NOTE Confidence: 0.856813196

00:22:17.490 --> 00:22:18.906 And with this,  
NOTE Confidence: 0.856813196

00:22:18.906 --> 00:22:22.510 I'm gonna stop sharing my presentation.  
NOTE Confidence: 0.856813196

00:22:22.510 --> 00:22:26.500 I'm going to let Doctor Shalin  
NOTE Confidence: 0.856813196

00:22:26.614 --> 00:22:29.522 Kothari take over and discuss  
NOTE Confidence: 0.856813196

00:22:29.522 --> 00:22:31.162 Mandelson and aggressive lymphomas  
NOTE Confidence: 0.856813196

00:22:31.162 --> 00:22:33.164 and I'm happy to take any question  
NOTE Confidence: 0.856813196

00:22:33.164 --> 00:22:34.879 at the end of the presentation.  
NOTE Confidence: 0.3599245

00:22:43.470 --> 00:22:49.100 But. One second. OK, can you see my screen?  
NOTE Confidence: 0.8666413

00:22:51.420 --> 00:22:54.348 We see your PowerPoint. You want perfect?  
NOTE Confidence: 0.85936822

00:22:56.370 --> 00:22:57.679 Slide show if you want to go.  
NOTE Confidence: 0.9293418

00:23:04.820 --> 00:23:05.240 Perfect.  
NOTE Confidence: 0.847445003333333

00:23:06.640 --> 00:23:08.761 So I'm going to focus more mainly  
NOTE Confidence: 0.847445003333333

00:23:08.761 --> 00:23:10.779 on large B cell lymphomas,  
NOTE Confidence: 0.847445003333333

00:23:10.780 --> 00:23:12.980 mainly aggressive B cell lymphomas

NOTE Confidence: 0.847445003333333

00:23:12.980 --> 00:23:15.690 and mental cell lymphoma have no

NOTE Confidence: 0.847445003333333

00:23:15.690 --> 00:23:18.065 relevant conflicts of interest to

NOTE Confidence: 0.847445003333333

00:23:18.065 --> 00:23:20.620 disclose for this presentation.

NOTE Confidence: 0.847445003333333

00:23:20.620 --> 00:23:23.595 The first abstract I chose was a

NOTE Confidence: 0.847445003333333

00:23:23.595 --> 00:23:25.343 biomarker driven treatment strategy

NOTE Confidence: 0.847445003333333

00:23:25.343 --> 00:23:28.115 in high risk large B cell lymphoma.

NOTE Confidence: 0.847445003333333

00:23:28.120 --> 00:23:30.976 The final results of a Nordic phase

NOTE Confidence: 0.847445003333333

00:23:30.976 --> 00:23:34.240 two study they this study included

NOTE Confidence: 0.847445003333333

00:23:34.240 --> 00:23:38.308 patients from 18 to 65 years of age.

NOTE Confidence: 0.847445003333333

00:23:38.308 --> 00:23:39.936 Histologically confirmed CD 20

NOTE Confidence: 0.847445003333333

00:23:39.936 --> 00:23:42.601 positive DLBCL, including Hygrid B,

NOTE Confidence: 0.847445003333333

00:23:42.601 --> 00:23:45.686 cell lymphomas and follicular 3B.

NOTE Confidence: 0.847445003333333

00:23:45.690 --> 00:23:48.345 They had to have at least stage two where

NOTE Confidence: 0.847445003333333

00:23:48.345 --> 00:23:51.270 the age adjusted IPS score of two to three.

NOTE Confidence: 0.847445003333333

00:23:51.270 --> 00:23:54.119 Uh with more than one external site

NOTE Confidence: 0.847445003333333

00:23:54.119 --> 00:23:56.382 of disease testicular lymphoma and  
NOTE Confidence: 0.8474450033333333

00:23:56.382 --> 00:23:58.342 paranasal sinus and orbital lymphoma  
NOTE Confidence: 0.8474450033333333

00:23:58.342 --> 00:24:00.530 with the destruction of the bone.  
NOTE Confidence: 0.8474450033333333

00:24:00.530 --> 00:24:02.650 And these are the clinical  
NOTE Confidence: 0.8474450033333333

00:24:02.650 --> 00:24:04.346 characteristics which are not  
NOTE Confidence: 0.8474450033333333

00:24:04.346 --> 00:24:06.750 too relevant to our discussion,  
NOTE Confidence: 0.8474450033333333

00:24:06.750 --> 00:24:09.710 but to kind of point out major pointers  
NOTE Confidence: 0.8474450033333333

00:24:09.710 --> 00:24:11.964 here that there are significant  
NOTE Confidence: 0.8474450033333333

00:24:11.964 --> 00:24:14.832 portion of patients with DLBCL Nos.  
NOTE Confidence: 0.8474450033333333

00:24:14.840 --> 00:24:17.451 With double hit and triple hit lymphomas  
NOTE Confidence: 0.8474450033333333

00:24:17.451 --> 00:24:20.509 and high risk biological characteristics.  
NOTE Confidence: 0.82452528

00:24:23.860 --> 00:24:26.940 The way this study was run was  
NOTE Confidence: 0.82452528

00:24:26.940 --> 00:24:28.752 patients were allowed to get some  
NOTE Confidence: 0.82452528

00:24:28.752 --> 00:24:30.520 pre phase therapy if required.  
NOTE Confidence: 0.82452528

00:24:30.520 --> 00:24:32.326 They received 2 cycles of our  
NOTE Confidence: 0.82452528

00:24:32.326 --> 00:24:33.937 chop followed by interim staging

NOTE Confidence: 0.82452528

00:24:33.937 --> 00:24:36.043 and they were stratified based on

NOTE Confidence: 0.82452528

00:24:36.043 --> 00:24:37.600 these biological risk factors.

NOTE Confidence: 0.82452528

00:24:37.600 --> 00:24:40.440 So if they had one of these risk

NOTE Confidence: 0.82452528

00:24:40.440 --> 00:24:42.535 factors positive then they were

NOTE Confidence: 0.82452528

00:24:42.535 --> 00:24:44.710 escalated to receive those adjusted

NOTE Confidence: 0.82452528

00:24:44.710 --> 00:24:47.227 epoch for four cycles followed by

NOTE Confidence: 0.82452528

00:24:47.227 --> 00:24:49.579 rituximab with high dose Ara C

NOTE Confidence: 0.82452528

00:24:49.580 --> 00:24:51.764 with final staging via a PET scan

NOTE Confidence: 0.82452528

00:24:51.764 --> 00:24:54.069 if there are biological factors.

NOTE Confidence: 0.82452528

00:24:54.070 --> 00:24:57.828 Are negative then instead of infusional

NOTE Confidence: 0.82452528

00:24:57.828 --> 00:25:01.476 strategy R2 app was given for four

NOTE Confidence: 0.82452528

00:25:01.476 --> 00:25:05.032 cycles and then they were off study.

NOTE Confidence: 0.82452528

00:25:05.040 --> 00:25:06.550 And the biological risk factors

NOTE Confidence: 0.82452528

00:25:06.550 --> 00:25:08.060 included are all clinically relevant,

NOTE Confidence: 0.82452528

00:25:08.060 --> 00:25:10.676 something that we always do in the clinic.

NOTE Confidence: 0.82452528

00:25:10.680 --> 00:25:13.084 So single Mic rearrangement,  
NOTE Confidence: 0.82452528

00:25:13.084 --> 00:25:16.089 DHL double hit lymphoma or  
NOTE Confidence: 0.82452528

00:25:16.089 --> 00:25:18.630 double expressor lymphoma,  
NOTE Confidence: 0.82452528

00:25:18.630 --> 00:25:24.134 P53 positive by IHC or P53 deletion and CD5  
NOTE Confidence: 0.82452528

00:25:24.134 --> 00:25:28.278 positivity and these are the PFS curves.  
NOTE Confidence: 0.82452528

00:25:28.280 --> 00:25:31.864 So you can see that with this escalated  
NOTE Confidence: 0.82452528

00:25:31.864 --> 00:25:34.933 strategy they were able to improve  
NOTE Confidence: 0.82452528

00:25:34.933 --> 00:25:37.813 overall outcomes for biologically high  
NOTE Confidence: 0.82452528

00:25:37.813 --> 00:25:42.090 risk large B cell lymphomas with PFS  
NOTE Confidence: 0.82452528

00:25:42.197 --> 00:25:44.780 close to statistically insignificant  
NOTE Confidence: 0.82452528

00:25:44.780 --> 00:25:48.260 biologically low risk disease.  
NOTE Confidence: 0.82452528

00:25:48.260 --> 00:25:50.440 And if I were to,  
NOTE Confidence: 0.82452528

00:25:50.440 --> 00:25:52.670 you know further stratify the  
NOTE Confidence: 0.82452528

00:25:52.670 --> 00:25:55.444 high grade B cell lymphoma with  
NOTE Confidence: 0.82452528

00:25:55.444 --> 00:25:58.533 double hit disease had a similar.  
NOTE Confidence: 0.82452528

00:25:58.533 --> 00:26:01.959 DFS as biologically as some some



NOTE Confidence: 0.82452528  
00:26:01.959 --> 00:26:05.496 patients with no double hit lymphoma.  
NOTE Confidence: 0.82452528  
00:26:05.500 --> 00:26:08.398 Where this strategy did not fare well  
NOTE Confidence: 0.82452528  
00:26:08.398 --> 00:26:10.830 is in patients with TP53 deletion  
NOTE Confidence: 0.82452528  
00:26:10.830 --> 00:26:13.990 where I think we still need to figure  
NOTE Confidence: 0.82452528  
00:26:14.076 --> 00:26:16.818 out better strategies and a normal  
NOTE Confidence: 0.82452528  
00:26:16.818 --> 00:26:19.756 novel strategies such as car T cell  
NOTE Confidence: 0.82452528  
00:26:19.756 --> 00:26:22.018 therapy and and bispecific antibodies  
NOTE Confidence: 0.82452528  
00:26:22.018 --> 00:26:25.174 might be more helpful in upfront  
NOTE Confidence: 0.82452528  
00:26:25.174 --> 00:26:27.703 strategies for for TP53 aberrated disease.  
NOTE Confidence: 0.82452528  
00:26:27.703 --> 00:26:28.164 Umm.  
NOTE Confidence: 0.82452528  
00:26:28.164 --> 00:26:31.425 The next study I wanted to focus  
NOTE Confidence: 0.82452528  
00:26:31.425 --> 00:26:34.246 on is abstract 735 five year old  
NOTE Confidence: 0.82452528  
00:26:34.246 --> 00:26:36.873 five year survival results from  
NOTE Confidence: 0.82452528  
00:26:36.873 --> 00:26:39.768 remodel trial which showed improved  
NOTE Confidence: 0.82452528  
00:26:39.768 --> 00:26:42.451 outcomes in DLBCL molecular subgroups  
NOTE Confidence: 0.82452528

00:26:42.451 --> 00:26:45.493 from addition of MIB to archtop  
NOTE Confidence: 0.82452528

00:26:45.493 --> 00:26:47.590 immuno chemoimmunotherapy.  
NOTE Confidence: 0.82452528

00:26:47.590 --> 00:26:50.560 The study aim was based off.  
NOTE Confidence: 0.82452528

00:26:50.560 --> 00:26:52.224 Some preliminary preclinical data  
NOTE Confidence: 0.82452528

00:26:52.224 --> 00:26:54.304 that Bortezomib and in general  
NOTE Confidence: 0.82452528

00:26:54.304 --> 00:26:58.370 proteasome inhibitors would have.  
NOTE Confidence: 0.82452528

00:26:58.370 --> 00:27:01.366 If there is a signal in the  
NOTE Confidence: 0.82452528

00:27:01.366 --> 00:27:03.788 preclinical world for the better  
NOTE Confidence: 0.82452528

00:27:03.788 --> 00:27:06.408 outcomes with ABC DLBCL models,  
NOTE Confidence: 0.82452528

00:27:06.410 --> 00:27:09.626 so the study design was patients  
NOTE Confidence: 0.82452528

00:27:09.630 --> 00:27:12.440 who had advanced stage DLBCL,  
NOTE Confidence: 0.82452528

00:27:12.440 --> 00:27:13.493 they were consented,  
NOTE Confidence: 0.82452528

00:27:13.493 --> 00:27:15.950 eventually received first cycle of our job.  
NOTE Confidence: 0.82452528

00:27:15.950 --> 00:27:17.930 While they were receiving that cycle,  
NOTE Confidence: 0.82452528

00:27:17.930 --> 00:27:20.460 biopsy was sent for molecular  
NOTE Confidence: 0.82452528

00:27:20.460 --> 00:27:23.881 profiling and mainly it was genus

NOTE Confidence: 0.82452528

00:27:23.881 --> 00:27:26.278 expression profiling platform.

NOTE Confidence: 0.82452528

00:27:26.280 --> 00:27:28.165 And then there were stratified

NOTE Confidence: 0.82452528

00:27:28.165 --> 00:27:30.050 based on molecular phenotype and

NOTE Confidence: 0.82452528

00:27:30.111 --> 00:27:32.354 IPI score and they were randomized

NOTE Confidence: 0.82452528

00:27:32.354 --> 00:27:34.910 to receive five more cycles of

NOTE Confidence: 0.82452528

00:27:34.996 --> 00:27:37.324 our job with Bortezomib or five

NOTE Confidence: 0.82452528

00:27:37.324 --> 00:27:39.420 cycles of our chop alone.

NOTE Confidence: 0.82452528

00:27:39.420 --> 00:27:41.448 Important to point out here that

NOTE Confidence: 0.82452528

00:27:41.448 --> 00:27:44.067 the the the there was an amendment

NOTE Confidence: 0.82452528

00:27:44.067 --> 00:27:46.461 where the dose of Bortezomib was

NOTE Confidence: 0.82452528

00:27:46.461 --> 00:27:48.103 increased from 1.3 to 1.6.

NOTE Confidence: 0.82452528

00:27:48.103 --> 00:27:50.210 In the middle of the trial there

NOTE Confidence: 0.82452528

00:27:50.282 --> 00:27:52.367 was interim analysis which showed

NOTE Confidence: 0.82452528

00:27:52.367 --> 00:27:54.939 that the benefit was mainly in the

NOTE Confidence: 0.82452528

00:27:54.940 --> 00:27:57.390 ABC's phenotype and hence they

NOTE Confidence: 0.82452528

00:27:57.390 --> 00:27:59.840 adjusted some of their parameters,  
NOTE Confidence: 0.82452528

00:27:59.840 --> 00:28:01.980 analysis parameters based on that.  
NOTE Confidence: 0.919682841428571

00:28:04.170 --> 00:28:07.348 And this is the distribution of patients.  
NOTE Confidence: 0.919682841428571

00:28:07.350 --> 00:28:09.835 It was nicely balanced between  
NOTE Confidence: 0.919682841428571

00:28:09.835 --> 00:28:12.350 the two groups and between  
NOTE Confidence: 0.919682841428571

00:28:12.350 --> 00:28:14.390 the two treatment modalities.  
NOTE Confidence: 0.919682841428571

00:28:14.390 --> 00:28:16.310 And these are the results.  
NOTE Confidence: 0.919682841428571

00:28:16.310 --> 00:28:20.206 So you can see that there's a clear  
NOTE Confidence: 0.919682841428571

00:28:20.206 --> 00:28:22.510 difference and statistically significant  
NOTE Confidence: 0.919682841428571

00:28:22.510 --> 00:28:27.670 PFS and OS benefit in ABC DLBCL in  
NOTE Confidence: 0.919682841428571

00:28:27.670 --> 00:28:32.010 contrast to GCB DLBCL molecular high.  
NOTE Confidence: 0.919682841428571

00:28:32.010 --> 00:28:35.440 High risk group or as a subgroup  
NOTE Confidence: 0.919682841428571

00:28:35.440 --> 00:28:37.599 that they had defined.  
NOTE Confidence: 0.919682841428571

00:28:37.600 --> 00:28:40.642 It was a predefined subgroup based  
NOTE Confidence: 0.919682841428571

00:28:40.642 --> 00:28:42.670 on multiple different parameters  
NOTE Confidence: 0.919682841428571

00:28:42.753 --> 00:28:45.777 put together as part of the gene

NOTE Confidence: 0.919682841428571

00:28:45.777 --> 00:28:47.703 expression profiling and that

NOTE Confidence: 0.919682841428571

00:28:47.703 --> 00:28:49.923 group also showed statistically

NOTE Confidence: 0.919682841428571

00:28:49.923 --> 00:28:52.482 significant difference in PFS with

NOTE Confidence: 0.919682841428571

00:28:52.482 --> 00:28:54.474 addition of Bortezomib to our job.

NOTE Confidence: 0.826643682857143

00:28:56.690 --> 00:29:00.146 The next study I I wanted to focus on

NOTE Confidence: 0.826643682857143

00:29:00.146 --> 00:29:04.533 is a prognostic index called Lab Pi in

NOTE Confidence: 0.826643682857143

00:29:04.533 --> 00:29:08.808 DLBCL validation study on behalf of the

NOTE Confidence: 0.826643682857143

00:29:08.808 --> 00:29:11.308 Spanish Lymphoma Cooperative group.

NOTE Confidence: 0.826643682857143

00:29:11.310 --> 00:29:14.610 So here I'm showing all these

NOTE Confidence: 0.826643682857143

00:29:14.610 --> 00:29:16.810 different prognostic variables that

NOTE Confidence: 0.826643682857143

00:29:16.903 --> 00:29:19.525 we sometimes use in the clinic.

NOTE Confidence: 0.826643682857143

00:29:19.530 --> 00:29:21.666 But mainly we rely, as we all know,

NOTE Confidence: 0.826643682857143

00:29:21.670 --> 00:29:26.070 in on our IPI&RPI.

NOTE Confidence: 0.826643682857143

00:29:26.070 --> 00:29:28.900 These authors designed a prognostic

NOTE Confidence: 0.826643682857143

00:29:28.900 --> 00:29:32.320 parameters which are much easier to do,

NOTE Confidence: 0.826643682857143

00:29:32.320 --> 00:29:36.292 cheaper to do and more easily  
NOTE Confidence: 0.826643682857143

00:29:36.292 --> 00:29:38.868 available in developing countries.  
NOTE Confidence: 0.826643682857143

00:29:38.868 --> 00:29:42.612 So the the the three parameters  
NOTE Confidence: 0.826643682857143

00:29:42.612 --> 00:29:45.482 included high LDH anemia of less  
NOTE Confidence: 0.826643682857143

00:29:45.482 --> 00:29:48.978 than 12 in men and 13.5 in females,  
NOTE Confidence: 0.826643682857143

00:29:48.978 --> 00:29:51.608 high beta 2 microglobulin for  
NOTE Confidence: 0.826643682857143

00:29:51.608 --> 00:29:54.807 and two points for high beta,  
NOTE Confidence: 0.826643682857143

00:29:54.810 --> 00:29:56.560 remarkably more than 4 milligram.  
NOTE Confidence: 0.826643682857143

00:29:56.560 --> 00:29:58.806 Or leader?  
NOTE Confidence: 0.826643682857143

00:29:58.806 --> 00:29:59.929 Umm.  
NOTE Confidence: 0.826643682857143

00:29:59.930 --> 00:30:03.080 So what they they authors go  
NOTE Confidence: 0.826643682857143

00:30:03.080 --> 00:30:06.164 to an extensive length to show  
NOTE Confidence: 0.826643682857143

00:30:06.164 --> 00:30:09.026 that this this particular index  
NOTE Confidence: 0.826643682857143

00:30:09.026 --> 00:30:11.674 is predictive and prognostic.  
NOTE Confidence: 0.826643682857143

00:30:11.680 --> 00:30:13.618 But I'm just showing the EFS  
NOTE Confidence: 0.826643682857143

00:30:13.618 --> 00:30:14.910 and OS curves here,

NOTE Confidence: 0.826643682857143

00:30:14.910 --> 00:30:18.204 and they nicely correlate with the

NOTE Confidence: 0.826643682857143

00:30:18.204 --> 00:30:21.889 IPI score that we use commonly.

NOTE Confidence: 0.826643682857143

00:30:21.890 --> 00:30:23.880 Based on stratification based on

NOTE Confidence: 0.826643682857143

00:30:23.880 --> 00:30:27.480 the points of 01 to 2-3 and four,

NOTE Confidence: 0.826643682857143

00:30:27.480 --> 00:30:28.984 which corresponds to lower,

NOTE Confidence: 0.826643682857143

00:30:28.984 --> 00:30:30.536 lower, intermediate, high,

NOTE Confidence: 0.826643682857143

00:30:30.536 --> 00:30:33.530 intermediate and high IPI scores.

NOTE Confidence: 0.757075532352941

00:30:35.640 --> 00:30:39.056 The next abstract that I wanted to focus

NOTE Confidence: 0.757075532352941

00:30:39.056 --> 00:30:42.295 on is a polatuzumab vedotin combined

NOTE Confidence: 0.757075532352941

00:30:42.295 --> 00:30:46.860 with rice or our ice as second line

NOTE Confidence: 0.757075532352941

00:30:46.860 --> 00:30:49.710 therapy in relapsed refractory DLBCL.

NOTE Confidence: 0.757075532352941

00:30:49.710 --> 00:30:51.488 So as we know the current standard

NOTE Confidence: 0.757075532352941

00:30:51.488 --> 00:30:53.093 of care in relapsed refractory

NOTE Confidence: 0.757075532352941

00:30:53.093 --> 00:30:55.427 DLBCL relapsing more than one year,

NOTE Confidence: 0.757075532352941

00:30:55.430 --> 00:30:58.069 so not primary refractory after first line

NOTE Confidence: 0.757075532352941

00:30:58.069 --> 00:31:00.268 treatment is salvage treatment followed  
NOTE Confidence: 0.757075532352941

00:31:00.268 --> 00:31:02.788 by autologous stem cell transplantation.  
NOTE Confidence: 0.757075532352941

00:31:02.790 --> 00:31:05.160 So the hypothesis for this study.  
NOTE Confidence: 0.757075532352941

00:31:05.160 --> 00:31:07.570 Was that polatuzumab vedotin combined  
NOTE Confidence: 0.757075532352941

00:31:07.570 --> 00:31:09.498 with rice salvage chemotherapy  
NOTE Confidence: 0.757075532352941

00:31:09.498 --> 00:31:11.709 as first salvage treatment would  
NOTE Confidence: 0.757075532352941

00:31:11.709 --> 00:31:14.193 be safe and effective bridge to  
NOTE Confidence: 0.757075532352941

00:31:14.266 --> 00:31:16.438 autologous stem cell transplant.  
NOTE Confidence: 0.757075532352941

00:31:16.440 --> 00:31:20.580 The inclusion criteria was pretty broad.  
NOTE Confidence: 0.757075532352941

00:31:20.580 --> 00:31:22.620 Adult patients with performance status  
NOTE Confidence: 0.757075532352941

00:31:22.620 --> 00:31:25.733 of zero to two with relapse refractory  
NOTE Confidence: 0.757075532352941

00:31:25.733 --> 00:31:28.679 disease after first line therapy that  
NOTE Confidence: 0.757075532352941

00:31:28.679 --> 00:31:31.338 must have included anthracycline.  
NOTE Confidence: 0.757075532352941

00:31:31.340 --> 00:31:34.560 It also included transformed DLBCL,  
NOTE Confidence: 0.757075532352941

00:31:34.560 --> 00:31:38.494 PMBCL and high grade B cell lymphomas.  
NOTE Confidence: 0.757075532352941

00:31:38.500 --> 00:31:41.328 And they of course have to be



NOTE Confidence: 0.757075532352941

00:31:41.328 --> 00:31:43.662 transplant eligible and this is

NOTE Confidence: 0.757075532352941

00:31:43.662 --> 00:31:45.682 the patient characteristic table.

NOTE Confidence: 0.757075532352941

00:31:45.682 --> 00:31:48.916 And it's important to note that there

NOTE Confidence: 0.757075532352941

00:31:48.916 --> 00:31:51.344 were equal distribution between primary

NOTE Confidence: 0.757075532352941

00:31:51.344 --> 00:31:53.799 refractory disease and relapse disease.

NOTE Confidence: 0.757075532352941

00:31:53.800 --> 00:31:58.035 Most patients were at stage four or

NOTE Confidence: 0.757075532352941

00:31:58.035 --> 00:32:02.137 three at advanced stage at at relapse

NOTE Confidence: 0.757075532352941

00:32:02.140 --> 00:32:05.318 and 78% of these patients had received

NOTE Confidence: 0.757075532352941

00:32:05.318 --> 00:32:09.410 our chop and 22% had received our epoch.

NOTE Confidence: 0.757075532352941

00:32:09.410 --> 00:32:11.846 And 17% of patients were double

NOTE Confidence: 0.757075532352941

00:32:11.846 --> 00:32:14.366 hit lymphoma and 34% were double

NOTE Confidence: 0.757075532352941

00:32:14.366 --> 00:32:15.230 expressor lymphoma.

NOTE Confidence: 0.757075532352941

00:32:15.230 --> 00:32:17.720 And something important to note out

NOTE Confidence: 0.757075532352941

00:32:17.720 --> 00:32:20.330 is that transformed lymphomas was a

NOTE Confidence: 0.757075532352941

00:32:20.330 --> 00:32:21.647 pretty significant representation

NOTE Confidence: 0.757075532352941

00:32:21.647 --> 00:32:25.090 with almost 30% of patients.  
NOTE Confidence: 0.757075532352941

00:32:25.090 --> 00:32:28.086 The way this salvage therapy was given  
NOTE Confidence: 0.757075532352941

00:32:28.086 --> 00:32:31.401 was at those level one basically it's it  
NOTE Confidence: 0.757075532352941

00:32:31.401 --> 00:32:34.180 was rice therapy in addition to polatuzumab,  
NOTE Confidence: 0.757075532352941

00:32:34.180 --> 00:32:36.644 the door to and given on day one  
NOTE Confidence: 0.757075532352941

00:32:36.644 --> 00:32:38.616 at 1.8 milligram per kilogram.  
NOTE Confidence: 0.757075532352941

00:32:38.616 --> 00:32:41.100 And then once patients had received  
NOTE Confidence: 0.757075532352941

00:32:41.170 --> 00:32:42.878 autologous stem cell transplantation  
NOTE Confidence: 0.757075532352941

00:32:42.878 --> 00:32:46.170 after two to three cycles of polar ice,  
NOTE Confidence: 0.757075532352941

00:32:46.170 --> 00:32:49.002 they would be eligible for polatuzumab  
NOTE Confidence: 0.757075532352941

00:32:49.002 --> 00:32:51.656 consolidation of three to four cycles  
NOTE Confidence: 0.757075532352941

00:32:51.656 --> 00:32:54.424 given every 21 days for a total of.  
NOTE Confidence: 0.757075532352941

00:32:54.430 --> 00:32:55.930 6 cycles.  
NOTE Confidence: 0.902269202

00:32:58.810 --> 00:33:01.410 And these are the results.  
NOTE Confidence: 0.902269202

00:33:01.410 --> 00:33:06.780 So you can see that a total of 441 patients  
NOTE Confidence: 0.902269202

00:33:06.780 --> 00:33:10.586 were evaluated and 22 patients were

NOTE Confidence: 0.902269202

00:33:10.586 --> 00:33:14.690 able to get stem cell transplantation.

NOTE Confidence: 0.902269202

00:33:14.690 --> 00:33:17.690 So the authors did note that this is

NOTE Confidence: 0.902269202

00:33:17.690 --> 00:33:20.702 definitely a low percentage and there is

NOTE Confidence: 0.902269202

00:33:20.702 --> 00:33:24.462 possibly a signal that pulled out in May

NOTE Confidence: 0.902269202

00:33:24.462 --> 00:33:27.606 potentially cause problems with stem cell.

NOTE Confidence: 0.902269202

00:33:27.610 --> 00:33:27.963 Mobilization,

NOTE Confidence: 0.902269202

00:33:27.963 --> 00:33:30.434 but that needs to be studied further.

NOTE Confidence: 0.902269202

00:33:30.440 --> 00:33:33.114 But what is important to note here

NOTE Confidence: 0.902269202

00:33:33.114 --> 00:33:36.685 is the PFS and OS curves which are

NOTE Confidence: 0.902269202

00:33:36.685 --> 00:33:39.450 very encouraging in otherwise a very

NOTE Confidence: 0.902269202

00:33:39.450 --> 00:33:42.330 heavily pretreated amid other more

NOTE Confidence: 0.902269202

00:33:42.330 --> 00:33:45.384 biologically high risk patient subgroup.

NOTE Confidence: 0.902269202

00:33:45.384 --> 00:33:49.356 So here I show primary refractory

NOTE Confidence: 0.902269202

00:33:49.356 --> 00:33:51.298 patients and relapsed disease.

NOTE Confidence: 0.902269202

00:33:51.298 --> 00:33:53.428 So clearly polarized regimen is

NOTE Confidence: 0.902269202

00:33:53.428 --> 00:33:55.810 not an effective second line  
NOTE Confidence: 0.902269202

00:33:55.810 --> 00:33:57.754 therapy for somebody with.  
NOTE Confidence: 0.902269202

00:33:57.760 --> 00:33:59.377 Primary refractory disease,  
NOTE Confidence: 0.902269202

00:33:59.377 --> 00:34:02.611 but for relapsed disease the PFS  
NOTE Confidence: 0.902269202

00:34:02.611 --> 00:34:05.072 curves look very encouraging and  
NOTE Confidence: 0.902269202

00:34:05.072 --> 00:34:08.310 this is the oral survival curve with.  
NOTE Confidence: 0.902269202

00:34:08.310 --> 00:34:10.008 You know the time to median  
NOTE Confidence: 0.902269202

00:34:10.008 --> 00:34:11.410 follow-up is still pretty low.  
NOTE Confidence: 0.902269202

00:34:11.410 --> 00:34:13.950 So we need to look at this data more with  
NOTE Confidence: 0.902269202

00:34:14.012 --> 00:34:16.490 more mature follow-up in upcoming years.  
NOTE Confidence: 0.902269202

00:34:16.490 --> 00:34:18.704 But the overall survival curves look  
NOTE Confidence: 0.902269202

00:34:18.704 --> 00:34:21.105 very encouraging in spite of many  
NOTE Confidence: 0.902269202

00:34:21.105 --> 00:34:23.250 patients not receiving stem cell  
NOTE Confidence: 0.902269202

00:34:23.250 --> 00:34:24.537 transplantation after polarize.  
NOTE Confidence: 0.7536891674

00:34:27.460 --> 00:34:29.900 The next abstract I wanted to focus on  
NOTE Confidence: 0.7536891674

00:34:29.900 --> 00:34:32.800 is Tafa Len in relapse refractory large

NOTE Confidence: 0.7536891674

00:34:32.800 --> 00:34:35.020 B cell lymphoma real-world outcomes

NOTE Confidence: 0.7536891674

00:34:35.094 --> 00:34:37.549 in a multicenter retrospective study.

NOTE Confidence: 0.7536891674

00:34:37.550 --> 00:34:41.357 And this is in contrast to the ALMINE trial.

NOTE Confidence: 0.7536891674

00:34:41.360 --> 00:34:43.999 And the authors go ahead and extensive

NOTE Confidence: 0.7536891674

00:34:43.999 --> 00:34:46.965 length to to compare the L mine

NOTE Confidence: 0.7536891674

00:34:46.965 --> 00:34:49.170 eligibility criteria and how Tafflin

NOTE Confidence: 0.7536891674

00:34:49.249 --> 00:34:52.140 is currently being used in the clinic.

NOTE Confidence: 0.7536891674

00:34:52.140 --> 00:34:54.370 And what these tables really

NOTE Confidence: 0.7536891674

00:34:54.370 --> 00:34:57.140 show here is that the real.

NOTE Confidence: 0.7536891674

00:34:57.140 --> 00:34:58.380 In the real world,

NOTE Confidence: 0.7536891674

00:34:58.380 --> 00:35:00.860 only 11% of patients would have

NOTE Confidence: 0.7536891674

00:35:00.860 --> 00:35:03.030 technically been eligible for L

NOTE Confidence: 0.7536891674

00:35:03.107 --> 00:35:05.781 mind and hence they wanted to see

NOTE Confidence: 0.7536891674

00:35:05.781 --> 00:35:08.342 whether this this difference in real

NOTE Confidence: 0.7536891674

00:35:08.342 --> 00:35:11.030 world versus the the trial data,

NOTE Confidence: 0.7536891674

00:35:11.030 --> 00:35:14.094 does that lead to any change in outcomes?  
NOTE Confidence: 0.7536891674

00:35:14.100 --> 00:35:15.536 And as we know,  
NOTE Confidence: 0.7536891674

00:35:15.536 --> 00:35:17.690 the reason this is a pertinent  
NOTE Confidence: 0.7536891674

00:35:17.772 --> 00:35:20.580 question is because in 2020 FDA  
NOTE Confidence: 0.7536891674

00:35:20.580 --> 00:35:23.056 gave an accelerated approval to  
NOTE Confidence: 0.7536891674

00:35:23.056 --> 00:35:25.641 tafinlar in patients with relapsed  
NOTE Confidence: 0.7536891674

00:35:25.641 --> 00:35:27.844 refractory DLBCL including transformed  
NOTE Confidence: 0.7536891674

00:35:27.844 --> 00:35:31.336 DLBCL who are not eligible for  
NOTE Confidence: 0.7536891674

00:35:31.336 --> 00:35:34.389 autologous stem cell transplantation.  
NOTE Confidence: 0.7536891674

00:35:34.390 --> 00:35:38.278 So these are the curves with a median PFS  
NOTE Confidence: 0.7536891674

00:35:38.278 --> 00:35:42.406 of 2.1 months and median OS seven months.  
NOTE Confidence: 0.7536891674

00:35:42.410 --> 00:35:45.010 So clearly.  
NOTE Confidence: 0.7536891674

00:35:45.010 --> 00:35:48.573 It leaves a lot desired and these  
NOTE Confidence: 0.7536891674

00:35:48.573 --> 00:35:51.360 data don't correspond with the  
NOTE Confidence: 0.7536891674

00:35:51.360 --> 00:35:54.270 trial data mainly authors conclude,  
NOTE Confidence: 0.7536891674

00:35:54.270 --> 00:35:57.406 because of its use in the real world,

NOTE Confidence: 0.7536891674

00:35:57.410 --> 00:36:00.450 which is not in congruence with the patient

NOTE Confidence: 0.7536891674

00:36:00.450 --> 00:36:02.568 population that was studied in mind.

NOTE Confidence: 0.7536891674

00:36:02.570 --> 00:36:04.070 So I think this trial,

NOTE Confidence: 0.7536891674

00:36:04.070 --> 00:36:05.954 this study is a good reminder

NOTE Confidence: 0.7536891674

00:36:05.954 --> 00:36:07.621 to look at patient population

NOTE Confidence: 0.7536891674

00:36:07.621 --> 00:36:09.697 for these trials and make sure

NOTE Confidence: 0.7536891674

00:36:09.697 --> 00:36:12.049 that we are using this patient,

NOTE Confidence: 0.7536891674

00:36:12.050 --> 00:36:14.204 this clinical option.

NOTE Confidence: 0.7536891674

00:36:14.204 --> 00:36:17.076 In an appropriate setting.

NOTE Confidence: 0.789045344444444

00:36:19.380 --> 00:36:22.425 The next abstract I wanted to focus

NOTE Confidence: 0.789045344444444

00:36:22.425 --> 00:36:25.405 on is the abstract number 555 risk

NOTE Confidence: 0.789045344444444

00:36:25.405 --> 00:36:28.010 of CNS involvement and high grade

NOTE Confidence: 0.789045344444444

00:36:28.010 --> 00:36:30.957 B cell lymphoma with Mick and BCL

NOTE Confidence: 0.789045344444444

00:36:30.957 --> 00:36:33.301 2 rearrangements analysis of a

NOTE Confidence: 0.789045344444444

00:36:33.301 --> 00:36:35.671 population based cohort with routine

NOTE Confidence: 0.789045344444444

00:36:35.671 --> 00:36:37.916 fish testing in British Columbia.  
NOTE Confidence: 0.7890453444444444

00:36:37.916 --> 00:36:40.940 So as we have discussed in previous  
NOTE Confidence: 0.7890453444444444

00:36:41.021 --> 00:36:44.009 ASC PME is there is a flurry of data  
NOTE Confidence: 0.7890453444444444

00:36:44.009 --> 00:36:46.619 coming out although I'll be all  
NOTE Confidence: 0.7890453444444444

00:36:46.619 --> 00:36:49.566 retrospective but with very high numbers.  
NOTE Confidence: 0.7890453444444444

00:36:49.566 --> 00:36:54.215 With high confidence that that we we  
NOTE Confidence: 0.7890453444444444

00:36:54.215 --> 00:36:56.990 don't necessarily have good effective  
NOTE Confidence: 0.7890453444444444

00:36:56.990 --> 00:36:59.865 strategies for CNS prophylaxis and  
NOTE Confidence: 0.7890453444444444

00:36:59.865 --> 00:37:01.640 this particular study is focused  
NOTE Confidence: 0.7890453444444444

00:37:01.640 --> 00:37:04.188 mainly in high grade B cell lymphomas.  
NOTE Confidence: 0.7890453444444444

00:37:04.190 --> 00:37:07.886 So they have these two subgroups  
NOTE Confidence: 0.7890453444444444

00:37:07.890 --> 00:37:10.910 based on pre fish like.  
NOTE Confidence: 0.7890453444444444

00:37:10.910 --> 00:37:13.118 So the present subgroup is what  
NOTE Confidence: 0.7890453444444444

00:37:13.118 --> 00:37:14.980 they call where prospectively the  
NOTE Confidence: 0.7890453444444444

00:37:14.980 --> 00:37:16.936 fish testing was done and the  
NOTE Confidence: 0.7890453444444444

00:37:16.936 --> 00:37:19.032 historic subgroup is where they had



NOTE Confidence: 0.7890453444444444

00:37:19.032 --> 00:37:20.088 to do retrospective.

NOTE Confidence: 0.7890453444444444

00:37:20.090 --> 00:37:23.577 Because in from 2005 to 2010 it was

NOTE Confidence: 0.7890453444444444

00:37:23.577 --> 00:37:27.210 not standard of care at that center.

NOTE Confidence: 0.7890453444444444

00:37:27.210 --> 00:37:29.870 And as you can see here patients,

NOTE Confidence: 0.7890453444444444

00:37:29.870 --> 00:37:32.574 these are all with high risk disease and

NOTE Confidence: 0.7890453444444444

00:37:32.574 --> 00:37:34.887 CNS prophylaxis was given in this fashion.

NOTE Confidence: 0.7890453444444444

00:37:34.890 --> 00:37:38.341 So 40% did not get any CNS

NOTE Confidence: 0.7890453444444444

00:37:38.341 --> 00:37:40.170 prophylaxis intrathecal therapy for

NOTE Confidence: 0.7890453444444444

00:37:40.170 --> 00:37:43.824 51% in the presence of group and

NOTE Confidence: 0.7890453444444444

00:37:43.824 --> 00:37:46.087 9% with intravenous prophylaxis.

NOTE Confidence: 0.7890453444444444

00:37:46.087 --> 00:37:50.140 So the authors show that the risk

NOTE Confidence: 0.7890453444444444

00:37:50.241 --> 00:37:53.328 for CNS relapse for this high risk

NOTE Confidence: 0.7890453444444444

00:37:53.328 --> 00:37:56.499 or high grade B cell lymphoma is.

NOTE Confidence: 0.7890453444444444

00:37:56.500 --> 00:37:57.822 Around 6%,

NOTE Confidence: 0.7890453444444444

00:37:57.822 --> 00:38:01.788 which is clearly a significant percentage

NOTE Confidence: 0.7890453444444444

00:38:01.788 --> 00:38:05.836 and higher than more low risk DLBCL.  
NOTE Confidence: 0.7890453444444444

00:38:05.840 --> 00:38:08.374 They show that CNS IPI scoring is  
NOTE Confidence: 0.7890453444444444

00:38:08.374 --> 00:38:10.660 still relevant in this current era  
NOTE Confidence: 0.7890453444444444

00:38:10.660 --> 00:38:13.292 even in hybrid we sell lymphomas and  
NOTE Confidence: 0.7890453444444444

00:38:13.365 --> 00:38:15.917 the high CNS IPS score is is able  
NOTE Confidence: 0.7890453444444444

00:38:15.917 --> 00:38:18.570 to identify patients who are at a  
NOTE Confidence: 0.7890453444444444

00:38:18.570 --> 00:38:21.646 higher risk for CNS relapse, but then.  
NOTE Confidence: 0.7890453444444444

00:38:21.646 --> 00:38:25.595 When we look at all patients in  
NOTE Confidence: 0.7890453444444444

00:38:25.595 --> 00:38:28.620 this subgroup in this study,  
NOTE Confidence: 0.7890453444444444

00:38:28.620 --> 00:38:31.756 whether they received CNS prophylaxis or not,  
NOTE Confidence: 0.7890453444444444

00:38:31.760 --> 00:38:34.865 it really didn't change the  
NOTE Confidence: 0.7890453444444444

00:38:34.865 --> 00:38:37.970 cumulative incidence of CNS relapse.  
NOTE Confidence: 0.7890453444444444

00:38:37.970 --> 00:38:41.106 And even when I looked into the  
NOTE Confidence: 0.7890453444444444

00:38:41.106 --> 00:38:44.479 subpopulation of high CNS IPI score patients,  
NOTE Confidence: 0.7890453444444444

00:38:44.480 --> 00:38:46.895 we still did not see any difference  
NOTE Confidence: 0.7890453444444444

00:38:46.895 --> 00:38:49.460 between patients who received CNS

NOTE Confidence: 0.789045344444444

00:38:49.460 --> 00:38:51.680 prophylaxis versus who didn't.

NOTE Confidence: 0.789045344444444

00:38:51.680 --> 00:38:52.652 Of course, um,

NOTE Confidence: 0.789045344444444

00:38:52.652 --> 00:38:54.920 I wouldn't make too much of this

NOTE Confidence: 0.789045344444444

00:38:54.996 --> 00:38:57.336 particular curve of CNS prophylaxis

NOTE Confidence: 0.789045344444444

00:38:57.336 --> 00:38:59.208 by modality of treatment,

NOTE Confidence: 0.789045344444444

00:38:59.210 --> 00:39:02.570 but clearly goes to show that.

NOTE Confidence: 0.789045344444444

00:39:02.570 --> 00:39:05.730 The common perception that intravenous

NOTE Confidence: 0.789045344444444

00:39:05.730 --> 00:39:08.890 therapy is potentially a better

NOTE Confidence: 0.789045344444444

00:39:08.981 --> 00:39:11.686 strategy is probably not true,

NOTE Confidence: 0.789045344444444

00:39:11.690 --> 00:39:15.183 and we need more trials to identify

NOTE Confidence: 0.789045344444444

00:39:15.183 --> 00:39:18.720 more effective CNS prophylaxis regimens.

NOTE Confidence: 0.7670133785

00:39:21.070 --> 00:39:24.976 Next, umm and my last abstract for

NOTE Confidence: 0.7670133785

00:39:24.976 --> 00:39:28.314 this meeting is abstract #1 which

NOTE Confidence: 0.7670133785

00:39:28.314 --> 00:39:30.582 was a plenary session paper which is

NOTE Confidence: 0.7670133785

00:39:30.582 --> 00:39:32.871 the efficacy and safety of ibrutinib

NOTE Confidence: 0.7670133785

00:39:32.871 --> 00:39:34.846 combined with standard first line  
NOTE Confidence: 0.7670133785

00:39:34.846 --> 00:39:37.275 treatment or a substitute for autologous  
NOTE Confidence: 0.7670133785

00:39:37.275 --> 00:39:39.250 stem cell transplantation in younger  
NOTE Confidence: 0.7670133785

00:39:39.250 --> 00:39:41.770 patients with mantle cell lymphoma,  
NOTE Confidence: 0.7670133785

00:39:41.770 --> 00:39:43.975 results from the randomized triangle  
NOTE Confidence: 0.7670133785

00:39:43.975 --> 00:39:46.820 trial by the European MCL network.  
NOTE Confidence: 0.838598972083333

00:39:49.290 --> 00:39:52.080 This particular trial included MCL  
NOTE Confidence: 0.838598972083333

00:39:52.080 --> 00:39:54.870 patients who were previously untreated  
NOTE Confidence: 0.838598972083333

00:39:54.955 --> 00:39:57.846 with stage two through 4 disease who  
NOTE Confidence: 0.838598972083333

00:39:57.846 --> 00:40:00.389 were younger than 66 years of age,  
NOTE Confidence: 0.838598972083333

00:40:00.390 --> 00:40:03.372 and of course they were suitable for  
NOTE Confidence: 0.838598972083333

00:40:03.372 --> 00:40:06.681 transplant or and hydros chemotherapy with  
NOTE Confidence: 0.838598972083333

00:40:06.681 --> 00:40:09.838 ECOG performance status of 0 through 2.  
NOTE Confidence: 0.838598972083333

00:40:09.840 --> 00:40:11.552 The primary outcome being  
NOTE Confidence: 0.838598972083333

00:40:11.552 --> 00:40:12.836 failure free survival.  
NOTE Confidence: 0.838598972083333

00:40:12.840 --> 00:40:14.933 So it's important to understand how the

NOTE Confidence: 0.838598972083333

00:40:14.933 --> 00:40:17.079 trial was designed between the three arms.

NOTE Confidence: 0.838598972083333

00:40:17.080 --> 00:40:18.528 So arm A is.

NOTE Confidence: 0.838598972083333

00:40:18.528 --> 00:40:20.700 So in all the three arms,

NOTE Confidence: 0.838598972083333

00:40:20.700 --> 00:40:23.450 the backbone of chemotherapy was

NOTE Confidence: 0.838598972083333

00:40:23.450 --> 00:40:25.650 anthracycline containing and cytarabine

NOTE Confidence: 0.838598972083333

00:40:25.650 --> 00:40:27.838 containing regimen archtop Rd.

NOTE Confidence: 0.838598972083333

00:40:27.838 --> 00:40:30.583 have alternating for a total

NOTE Confidence: 0.838598972083333

00:40:30.583 --> 00:40:32.820 of three cycles each.

NOTE Confidence: 0.838598972083333

00:40:32.820 --> 00:40:34.983 And then the difference between the two

NOTE Confidence: 0.838598972083333

00:40:34.983 --> 00:40:37.658 arms is based on whether the patients

NOTE Confidence: 0.838598972083333

00:40:37.658 --> 00:40:39.763 received autologous stem cell transplant.

NOTE Confidence: 0.838598972083333

00:40:39.770 --> 00:40:40.608 Um um.

NOTE Confidence: 0.838598972083333

00:40:40.608 --> 00:40:41.027 Yeah.

NOTE Confidence: 0.838598972083333

00:40:41.027 --> 00:40:43.122 Or versus patients who did

NOTE Confidence: 0.838598972083333

00:40:43.122 --> 00:40:45.165 not receive autologous stepsis

NOTE Confidence: 0.838598972083333

00:40:45.165 --> 00:40:47.960 transmit and only received two  
NOTE Confidence: 0.838598972083333

00:40:47.960 --> 00:40:50.710 years of ibrutinib maintenance.  
NOTE Confidence: 0.838598972083333

00:40:50.710 --> 00:40:53.958 The first arm did not receive a brute  
NOTE Confidence: 0.838598972083333

00:40:53.958 --> 00:40:57.565 nib along with the R Chop rdhap versus  
NOTE Confidence: 0.838598972083333

00:40:57.565 --> 00:40:59.885 these two arms received ibrutinib  
NOTE Confidence: 0.838598972083333

00:40:59.885 --> 00:41:02.872 as part of the chemo regimen itself.  
NOTE Confidence: 0.838598972083333

00:41:02.872 --> 00:41:05.749 And important to note which is talked  
NOTE Confidence: 0.838598972083333

00:41:05.749 --> 00:41:08.155 about less when we talk about this  
NOTE Confidence: 0.838598972083333

00:41:08.155 --> 00:41:10.721 trial is that our maintenance was  
NOTE Confidence: 0.838598972083333

00:41:10.721 --> 00:41:13.137 added following national guidelines.  
NOTE Confidence: 0.838598972083333

00:41:13.140 --> 00:41:14.310 In all three trial arms,  
NOTE Confidence: 0.838598972083333

00:41:14.310 --> 00:41:15.480 so many patients,  
NOTE Confidence: 0.838598972083333

00:41:15.480 --> 00:41:18.210 actually almost half of the patients in  
NOTE Confidence: 0.838598972083333

00:41:18.287 --> 00:41:21.027 each arm received rituximab maintenance,  
NOTE Confidence: 0.838598972083333

00:41:21.030 --> 00:41:24.006 which is currently what we use in clinic.  
NOTE Confidence: 0.838598972083333

00:41:24.010 --> 00:41:26.440 So I would say that in all these arms,

NOTE Confidence: 0.838598972083333

00:41:26.440 --> 00:41:28.210 especially in these two arms,

NOTE Confidence: 0.838598972083333

00:41:28.210 --> 00:41:33.120 it was R + I maintenance for the most part.

NOTE Confidence: 0.838598972083333

00:41:33.120 --> 00:41:35.520 These are the patient characteristics.

NOTE Confidence: 0.838598972083333

00:41:35.520 --> 00:41:38.000 So I just wanted to point out that

NOTE Confidence: 0.838598972083333

00:41:38.000 --> 00:41:39.659 most patients were stage four

NOTE Confidence: 0.838598972083333

00:41:39.660 --> 00:41:43.975 approximately almost 90% in these three

NOTE Confidence: 0.838598972083333

00:41:43.975 --> 00:41:48.560 arms and 58% of patients were low,

NOTE Confidence: 0.838598972083333

00:41:48.560 --> 00:41:51.325 maybe around 30% were intermediate

NOTE Confidence: 0.838598972083333

00:41:51.325 --> 00:41:55.004 and 15 to 16% of high maybe patients

NOTE Confidence: 0.838598972083333

00:41:55.004 --> 00:41:56.834 were included in this trial.

NOTE Confidence: 0.80362338625

00:41:58.920 --> 00:42:00.810 And these are the important

NOTE Confidence: 0.80362338625

00:42:00.810 --> 00:42:03.225 curves out of this plenary session

NOTE Confidence: 0.80362338625

00:42:03.225 --> 00:42:05.500 paper of failure free survival.

NOTE Confidence: 0.80362338625

00:42:05.500 --> 00:42:09.724 And you can see that the arm where

NOTE Confidence: 0.80362338625

00:42:09.724 --> 00:42:11.708 patients received our chop Rd.

NOTE Confidence: 0.80362338625

00:42:11.708 --> 00:42:13.880 have followed by autologous stem cell  
NOTE Confidence: 0.80362338625

00:42:13.944 --> 00:42:16.399 transplantation had an inferior failure,  
NOTE Confidence: 0.80362338625

00:42:16.400 --> 00:42:20.125 free survival in contrast to  
NOTE Confidence: 0.80362338625

00:42:20.125 --> 00:42:22.360 ibrutinib containing arms.  
NOTE Confidence: 0.80362338625

00:42:22.360 --> 00:42:25.741 Now we need more time before we  
NOTE Confidence: 0.80362338625

00:42:25.741 --> 00:42:29.216 can tease those two cars out, but.  
NOTE Confidence: 0.80362338625

00:42:29.216 --> 00:42:32.572 Clearly we can say that addition  
NOTE Confidence: 0.80362338625

00:42:32.572 --> 00:42:34.676 of ibrutinib makes autologous  
NOTE Confidence: 0.80362338625

00:42:34.676 --> 00:42:37.383 stem cell transplant less relevant  
NOTE Confidence: 0.80362338625

00:42:37.383 --> 00:42:39.459 in the frontline setting.  
NOTE Confidence: 0.80362338625

00:42:39.460 --> 00:42:41.590 So that's pretty much the  
NOTE Confidence: 0.80362338625

00:42:41.590 --> 00:42:43.720 take away out of this.  
NOTE Confidence: 0.80362338625

00:42:43.720 --> 00:42:45.370 Study.  
NOTE Confidence: 0.80362338625

00:42:45.370 --> 00:42:47.826 And that difference between  
NOTE Confidence: 0.80362338625

00:42:47.826 --> 00:42:50.282 overall survival of ibrutinib  
NOTE Confidence: 0.80362338625

00:42:50.282 --> 00:42:52.704 containing arms versus non



NOTE Confidence: 0.80362338625

00:42:52.704 --> 00:42:55.469 ibrutinib containing arms is clear.

NOTE Confidence: 0.80362338625

00:42:55.470 --> 00:42:58.172 So the authors conclude that it overall

NOTE Confidence: 0.80362338625

00:42:58.172 --> 00:43:00.744 too early to evaluate statistical

NOTE Confidence: 0.80362338625

00:43:00.744 --> 00:43:03.416 significance of overall survival.

NOTE Confidence: 0.80362338625

00:43:03.420 --> 00:43:06.899 But there is definitely a very clear

NOTE Confidence: 0.80362338625

00:43:06.899 --> 00:43:10.110 signal that ibrutinib containing regimen,

NOTE Confidence: 0.80362338625

00:43:10.110 --> 00:43:12.497 we may be able to avoid autologous

NOTE Confidence: 0.80362338625

00:43:12.497 --> 00:43:13.938 stem cell transplant consolidation

NOTE Confidence: 0.80362338625

00:43:13.938 --> 00:43:16.374 in those patients as long as they

NOTE Confidence: 0.80362338625

00:43:16.374 --> 00:43:18.788 are able to receive it routine

NOTE Confidence: 0.80362338625

00:43:18.788 --> 00:43:20.858 maintenance with or without rituximab.

NOTE Confidence: 0.80362338625

00:43:20.860 --> 00:43:23.380 So authors conclude that A+

NOTE Confidence: 0.80362338625

00:43:23.380 --> 00:43:25.900 IR is superior to a.

NOTE Confidence: 0.80362338625

00:43:25.900 --> 00:43:27.910 The autologous stem cell transplant

NOTE Confidence: 0.80362338625

00:43:27.910 --> 00:43:29.920 is not superior to ibrutinib

NOTE Confidence: 0.80362338625

00:43:29.992 --> 00:43:31.852 containing regimens and currently  
NOTE Confidence: 0.80362338625

00:43:31.852 --> 00:43:34.177 no decision whether autologous stem  
NOTE Confidence: 0.80362338625

00:43:34.177 --> 00:43:36.538 cell transplant adds to ibrutinib.  
NOTE Confidence: 0.80362338625

00:43:36.540 --> 00:43:40.100 But toxicity favors ibrutinib only  
NOTE Confidence: 0.80362338625

00:43:40.100 --> 00:43:41.800 and numerical overall survival benefit  
NOTE Confidence: 0.80362338625

00:43:41.800 --> 00:43:43.820 was seen in the ibrutinib arms.  
NOTE Confidence: 0.923660708333333

00:43:46.040 --> 00:43:47.840 So this is my summary slide.  
NOTE Confidence: 0.923660708333333

00:43:47.840 --> 00:43:49.915 For mantle cell lymphoma and  
NOTE Confidence: 0.923660708333333

00:43:49.915 --> 00:43:52.702 large B cell lymphoma, our job Rd.  
NOTE Confidence: 0.923660708333333

00:43:52.702 --> 00:43:54.572 HAP with ibrutinib followed by  
NOTE Confidence: 0.923660708333333

00:43:54.572 --> 00:43:56.699 ibrutinib with or without a taxman.  
NOTE Confidence: 0.923660708333333

00:43:56.700 --> 00:43:59.200 Maintenance is an effective frontline  
NOTE Confidence: 0.923660708333333

00:43:59.200 --> 00:44:02.819 strategy in young and fit MCL patients.  
NOTE Confidence: 0.923660708333333

00:44:02.820 --> 00:44:05.075 Autologous stem cell transplant could  
NOTE Confidence: 0.923660708333333

00:44:05.075 --> 00:44:08.030 be safely avoided with this strategy.  
NOTE Confidence: 0.923660708333333

00:44:08.030 --> 00:44:10.522 Clinically available biomarker driven

NOTE Confidence: 0.923660708333333

00:44:10.522 --> 00:44:13.637 strategy to escalate traditional immuno

NOTE Confidence: 0.923660708333333

00:44:13.637 --> 00:44:15.989 chemotherapy could potentially help improve

NOTE Confidence: 0.923660708333333

00:44:15.989 --> 00:44:19.519 outcomes in high risk large B cell lymphoma.

NOTE Confidence: 0.923660708333333

00:44:19.520 --> 00:44:22.280 Addition of Bortezomib to Archtops shows

NOTE Confidence: 0.923660708333333

00:44:22.280 --> 00:44:25.399 improved outcomes in ABC subtype of DLBCL.

NOTE Confidence: 0.923660708333333

00:44:25.400 --> 00:44:28.200 In my opinion it would have been practice

NOTE Confidence: 0.923660708333333

00:44:28.200 --> 00:44:30.413 changing if gene expression profiling

NOTE Confidence: 0.923660708333333

00:44:30.413 --> 00:44:32.823 was readily available clinically which

NOTE Confidence: 0.923660708333333

00:44:32.823 --> 00:44:35.766 is which is not the case at this time.

NOTE Confidence: 0.923660708333333

00:44:35.770 --> 00:44:37.986 Lab Pi prognostic model,

NOTE Confidence: 0.923660708333333

00:44:37.986 --> 00:44:41.310 which includes LDH anemia and beta

NOTE Confidence: 0.923660708333333

00:44:41.407 --> 00:44:43.912 2 microglobulin, is a cheap,

NOTE Confidence: 0.923660708333333

00:44:43.912 --> 00:44:45.582 reproducible and effective tool that

NOTE Confidence: 0.923660708333333

00:44:45.582 --> 00:44:47.754 could be useful in some countries

NOTE Confidence: 0.923660708333333

00:44:47.754 --> 00:44:49.549 and in some clinical settings.

NOTE Confidence: 0.923660708333333

00:44:49.550 --> 00:44:51.246 Polarized followed by autologous  
NOTE Confidence: 0.923660708333333

00:44:51.246 --> 00:44:52.942 stem cell transplant consolidation  
NOTE Confidence: 0.923660708333333

00:44:52.942 --> 00:44:55.486 is an effective second line regimen  
NOTE Confidence: 0.923660708333333

00:44:55.486 --> 00:44:56.707 with good outcomes.  
NOTE Confidence: 0.923660708333333

00:44:56.710 --> 00:44:59.678 This off label regimen can be potentially  
NOTE Confidence: 0.923660708333333

00:44:59.678 --> 00:45:01.894 considered in patients with transformed  
NOTE Confidence: 0.923660708333333

00:45:01.894 --> 00:45:04.516 DLBCL who would not have otherwise  
NOTE Confidence: 0.923660708333333

00:45:04.516 --> 00:45:07.118 received polar in the frontline setting.  
NOTE Confidence: 0.923660708333333

00:45:07.120 --> 00:45:09.520 Tafa Len may be optimally suited  
NOTE Confidence: 0.923660708333333

00:45:09.520 --> 00:45:12.084 only for patients with fewer prior  
NOTE Confidence: 0.923660708333333

00:45:12.084 --> 00:45:14.748 lines of therapy and non refractory  
NOTE Confidence: 0.923660708333333

00:45:14.748 --> 00:45:17.340 disease so that it reflects Elmi  
NOTE Confidence: 0.923660708333333

00:45:17.340 --> 00:45:19.052 and clinical trial population.  
NOTE Confidence: 0.923660708333333

00:45:19.060 --> 00:45:20.060 And lastly,  
NOTE Confidence: 0.923660708333333

00:45:20.060 --> 00:45:22.060 currently utilized strategies for  
NOTE Confidence: 0.923660708333333

00:45:22.060 --> 00:45:24.995 CNS prophylaxis in high grade B

NOTE Confidence: 0.923660708333333  
00:45:24.995 --> 00:45:26.707 cell lymphomas are ineffective  
NOTE Confidence: 0.923660708333333  
00:45:26.707 --> 00:45:29.000 and more studies are needed.  
NOTE Confidence: 0.923660708333333  
00:45:29.000 --> 00:45:31.168 Thank you so much and now I'll pass  
NOTE Confidence: 0.923660708333333  
00:45:31.168 --> 00:45:33.738 on to Doctor Sethi to drive US home.  
NOTE Confidence: 0.721245302222222  
00:45:39.640 --> 00:45:41.692 Thank you Doctor uh Qatari for  
NOTE Confidence: 0.721245302222222  
00:45:41.692 --> 00:45:43.290 the excellent presentation, so.  
NOTE Confidence: 0.90884015  
00:45:46.120 --> 00:45:46.969 Let me just.  
NOTE Confidence: 0.957762222  
00:45:49.950 --> 00:45:50.930 Can you see my screen?  
NOTE Confidence: 0.848585272  
00:45:53.370 --> 00:45:55.310 We can see your PowerPoint. Yeah,  
NOTE Confidence: 0.848585272  
00:45:55.310 --> 00:45:56.930 you can just share your slides.  
NOTE Confidence: 0.8357622425  
00:45:58.860 --> 00:46:03.050 OK, here we go. All right.  
NOTE Confidence: 0.8357622425  
00:46:03.050 --> 00:46:05.633 Perfect. OK. Thank you. Alright,  
NOTE Confidence: 0.8357622425  
00:46:05.633 --> 00:46:07.897 so I will be focusing on 2 cell  
NOTE Confidence: 0.8357622425  
00:46:07.897 --> 00:46:09.508 lymphoma and Hodgkin lymphomas.  
NOTE Confidence: 0.740549048571429  
00:46:11.720 --> 00:46:15.155 So for the T cell lymphoma abstracts as  
NOTE Confidence: 0.740549048571429

00:46:15.155 --> 00:46:17.640 well As for the Hodgkin lymphoma abstracts,  
NOTE Confidence: 0.740549048571429

00:46:17.640 --> 00:46:20.736 my selection is most  
NOTE Confidence: 0.740549048571429

00:46:20.736 --> 00:46:23.058 focusing on immunotherapies.  
NOTE Confidence: 0.740549048571429

00:46:23.060 --> 00:46:26.280 Both in both the diseases.  
NOTE Confidence: 0.740549048571429

00:46:26.280 --> 00:46:28.278 So starting with the first abstract,  
NOTE Confidence: 0.740549048571429

00:46:28.280 --> 00:46:31.717 it's a phase one trial using nivolumab  
NOTE Confidence: 0.740549048571429

00:46:31.717 --> 00:46:34.318 in combination with dose adjusted  
NOTE Confidence: 0.740549048571429

00:46:34.318 --> 00:46:36.918 epoch in newly diagnosed PCL.  
NOTE Confidence: 0.740549048571429

00:46:36.920 --> 00:46:38.780 This was an investigator initiated  
NOTE Confidence: 0.740549048571429

00:46:38.780 --> 00:46:41.320 study by Doctor, Hamaker said.  
NOTE Confidence: 0.740549048571429

00:46:41.320 --> 00:46:43.450 University of Colorado,  
NOTE Confidence: 0.740549048571429

00:46:43.450 --> 00:46:45.650 so we know that those are just the  
NOTE Confidence: 0.740549048571429

00:46:45.650 --> 00:46:47.415 Deepak is available treatment option  
NOTE Confidence: 0.740549048571429

00:46:47.415 --> 00:46:50.089 in the first line for peripheral T  
NOTE Confidence: 0.740549048571429

00:46:50.152 --> 00:46:52.467 cell lymphomas regardless of subtype.  
NOTE Confidence: 0.740549048571429

00:46:52.470 --> 00:46:54.300 However, we also know that.

NOTE Confidence: 0.721655144

00:46:57.010 --> 00:47:00.126 With anthracycline based therapies 25% of.

NOTE Confidence: 0.721655144

00:47:00.126 --> 00:47:05.523 The five year old PFS in PCL is just 25%.

NOTE Confidence: 0.721655144

00:47:05.523 --> 00:47:08.274 So there is a great need to

NOTE Confidence: 0.721655144

00:47:08.274 --> 00:47:10.691 improve upon these under cycling

NOTE Confidence: 0.721655144

00:47:10.691 --> 00:47:13.775 based regimens in the first line.

NOTE Confidence: 0.721655144

00:47:13.780 --> 00:47:16.060 The issue with the immune checkpoint

NOTE Confidence: 0.721655144

00:47:16.060 --> 00:47:18.283 black blockade in T cell lymphomas

NOTE Confidence: 0.721655144

00:47:18.283 --> 00:47:20.827 is that there has been a risk of

NOTE Confidence: 0.721655144

00:47:20.904 --> 00:47:23.429 hyper progression noted in certain

NOTE Confidence: 0.721655144

00:47:23.429 --> 00:47:25.449 subtypes like specifically atll.

NOTE Confidence: 0.721655144

00:47:25.450 --> 00:47:27.166 Single agent immune checkpoint

NOTE Confidence: 0.721655144

00:47:27.166 --> 00:47:29.740 inhibitors had an overall response rate

NOTE Confidence: 0.721655144

00:47:29.807 --> 00:47:31.870 of 30% in heavily pretreated patients.

NOTE Confidence: 0.721655144

00:47:31.870 --> 00:47:35.182 But again single agent therapy in T cell

NOTE Confidence: 0.721655144

00:47:35.182 --> 00:47:38.010 lymphomas is not really the way forward

NOTE Confidence: 0.721655144

00:47:38.010 --> 00:47:40.880 because of the risk of hyper progression.  
NOTE Confidence: 0.721655144

00:47:40.880 --> 00:47:45.640 So this particular study wanted to look at.  
NOTE Confidence: 0.721655144

00:47:45.640 --> 00:47:47.800 The combination of cytotoxic therapy,  
NOTE Confidence: 0.721655144

00:47:47.800 --> 00:47:49.775 uh immune checkpoint and ambition  
NOTE Confidence: 0.721655144

00:47:49.775 --> 00:47:52.835 in the hope that the tissue injury  
NOTE Confidence: 0.721655144

00:47:52.835 --> 00:47:54.855 from chemotherapy will result  
NOTE Confidence: 0.721655144

00:47:54.855 --> 00:47:57.588 in new antigen expression and  
NOTE Confidence: 0.721655144

00:47:57.588 --> 00:47:59.508 increased tumor immunogenicity.  
NOTE Confidence: 0.721655144

00:47:59.510 --> 00:48:00.794 So umm.  
NOTE Confidence: 0.721655144

00:48:00.794 --> 00:48:04.004 Also in PTCL there is.  
NOTE Confidence: 0.903276655833333

00:48:13.850 --> 00:48:16.216 And we need more treatment options and  
NOTE Confidence: 0.903276655833333

00:48:16.216 --> 00:48:19.261 the other thing is that the with the  
NOTE Confidence: 0.903276655833333

00:48:19.261 --> 00:48:20.782 immunosuppressive microenvironment and  
NOTE Confidence: 0.903276655833333

00:48:20.782 --> 00:48:23.502 high mutational burden there is a. Risk.  
NOTE Confidence: 0.903276655833333

00:48:23.502 --> 00:48:27.034 Uh, there is a, you know, viable, uh,  
NOTE Confidence: 0.903276655833333

00:48:27.034 --> 00:48:30.560 reason why this would be effective.



NOTE Confidence: 0.76126266125

00:48:33.250 --> 00:48:36.466 So we looked at the combination of nivolumab,

NOTE Confidence: 0.76126266125

00:48:36.470 --> 00:48:41.214 so the and epoch in this study and.

NOTE Confidence: 0.76126266125

00:48:41.220 --> 00:48:43.428 The they use the flat dose

NOTE Confidence: 0.76126266125

00:48:43.428 --> 00:48:45.492 of nivolumab and the standard

NOTE Confidence: 0.76126266125

00:48:45.492 --> 00:48:48.037 dosing of dose adjusted epoch.

NOTE Confidence: 0.76126266125

00:48:48.040 --> 00:48:49.340 And they allowed those levels

NOTE Confidence: 0.76126266125

00:48:49.340 --> 00:48:50.870 starting at those level minus one.

NOTE Confidence: 0.8625798475

00:48:53.060 --> 00:48:54.900 So here, uh, the main thing I want

NOTE Confidence: 0.8625798475

00:48:54.900 --> 00:48:56.918 to focus on is that they included

NOTE Confidence: 0.8625798475

00:48:56.918 --> 00:48:58.418 a number of different subtypes,

NOTE Confidence: 0.8625798475

00:48:58.420 --> 00:48:59.956 also including primary cutaneous

NOTE Confidence: 0.8625798475

00:48:59.956 --> 00:49:01.876 gamma delta T cell lymphoma.

NOTE Confidence: 0.8625798475

00:49:01.880 --> 00:49:05.370 It is a an uncommon rare subtype.

NOTE Confidence: 0.8625798475

00:49:05.370 --> 00:49:07.500 However, you know this is something

NOTE Confidence: 0.8625798475

00:49:07.500 --> 00:49:09.982 we do come across in clinical

NOTE Confidence: 0.8625798475

00:49:09.982 --> 00:49:12.112 practice and I'm highlighting that  
NOTE Confidence: 0.8625798475

00:49:12.112 --> 00:49:14.318 because they found some durable  
NOTE Confidence: 0.8625798475

00:49:14.318 --> 00:49:16.030 responses in this population.  
NOTE Confidence: 0.8625798475

00:49:16.030 --> 00:49:17.986 So as expected patients did have  
NOTE Confidence: 0.8625798475

00:49:17.986 --> 00:49:20.049 a number of immune related side  
NOTE Confidence: 0.8625798475

00:49:20.049 --> 00:49:22.119 effects and here at least one  
NOTE Confidence: 0.8625798475

00:49:22.119 --> 00:49:24.159 patient had each of one of these  
NOTE Confidence: 0.8625798475

00:49:24.159 --> 00:49:27.290 that you can see in this figure.  
NOTE Confidence: 0.8625798475

00:49:27.290 --> 00:49:30.314 What they found was that the immune related  
NOTE Confidence: 0.8625798475

00:49:30.314 --> 00:49:32.770 side effects occurred early and that.  
NOTE Confidence: 0.8625798475

00:49:32.770 --> 00:49:38.139 A did lead to stopping new nivolumab  
NOTE Confidence: 0.8625798475

00:49:38.139 --> 00:49:40.779 and these you know in the in a  
NOTE Confidence: 0.8625798475

00:49:40.779 --> 00:49:42.895 subset of these patients because of  
NOTE Confidence: 0.8625798475

00:49:42.895 --> 00:49:44.965 the immune related side effects.  
NOTE Confidence: 0.8625798475

00:49:44.970 --> 00:49:46.346 What was really interesting  
NOTE Confidence: 0.8625798475

00:49:46.346 --> 00:49:48.874 was since the study did allow a

NOTE Confidence: 0.8625798475

00:49:48.874 --> 00:49:50.470 previous cycle of chemotherapy,

NOTE Confidence: 0.8625798475

00:49:50.470 --> 00:49:52.300 what they found was that the

NOTE Confidence: 0.8625798475

00:49:52.300 --> 00:49:53.972 patients who had previously received

NOTE Confidence: 0.8625798475

00:49:53.972 --> 00:49:55.957 chemotherapy and where the combined

NOTE Confidence: 0.8625798475

00:49:55.957 --> 00:49:57.545 combination was initiated as

NOTE Confidence: 0.8625798475

00:49:57.607 --> 00:49:59.347 cycle two rather than cycle one.

NOTE Confidence: 0.8625798475

00:49:59.350 --> 00:50:01.090 These patients had very few immune

NOTE Confidence: 0.8625798475

00:50:01.090 --> 00:50:02.800 related side effects and treatment.

NOTE Confidence: 0.8625798475

00:50:02.800 --> 00:50:03.680 Continuations.

NOTE Confidence: 0.8625798475

00:50:03.680 --> 00:50:08.564 So this strategy did somehow it was

NOTE Confidence: 0.8625798475

00:50:08.564 --> 00:50:10.500 like it was not really a planned thing.

NOTE Confidence: 0.8625798475

00:50:10.500 --> 00:50:13.307 It was just because these patients ended

NOTE Confidence: 0.8625798475

00:50:13.307 --> 00:50:15.873 up starting with cycle two that they

NOTE Confidence: 0.8625798475

00:50:15.873 --> 00:50:18.378 did find fewer immune related side effects.

NOTE Confidence: 0.8625798475

00:50:18.380 --> 00:50:22.509 So a potential strategy for future studies.

NOTE Confidence: 0.8625798475

00:50:22.509 --> 00:50:26.284 What they also saw that was that even  
NOTE Confidence: 0.8625798475

00:50:26.284 --> 00:50:29.343 though the the toxicity was seen early  
NOTE Confidence: 0.8625798475

00:50:29.343 --> 00:50:33.156 but a number of patients with both PR.  
NOTE Confidence: 0.8625798475

00:50:33.160 --> 00:50:36.072 As well as stable disease did did  
NOTE Confidence: 0.8625798475

00:50:36.072 --> 00:50:39.410 convert into ACR at the end of treatment.  
NOTE Confidence: 0.8625798475

00:50:39.410 --> 00:50:42.080 So necessarily the treatment was  
NOTE Confidence: 0.8625798475

00:50:42.080 --> 00:50:46.138 not you know the treatment as it was  
NOTE Confidence: 0.8625798475

00:50:46.138 --> 00:50:48.434 continued late responses were seen.  
NOTE Confidence: 0.8625798475

00:50:48.434 --> 00:50:51.540 Uh, here's the UM survival analysis curves.  
NOTE Confidence: 0.8625798475

00:50:51.540 --> 00:50:51.811 Uh,  
NOTE Confidence: 0.8625798475

00:50:51.811 --> 00:50:53.708 so the at a median follow-up of  
NOTE Confidence: 0.8625798475

00:50:53.708 --> 00:50:54.680 about two years,  
NOTE Confidence: 0.8625798475

00:50:54.680 --> 00:50:59.078 the median progression free survival was.  
NOTE Confidence: 0.8625798475

00:50:59.080 --> 00:51:01.582 For 34 days and overall survival  
NOTE Confidence: 0.8625798475

00:51:01.582 --> 00:51:02.810 was 714 days.  
NOTE Confidence: 0.862903195555556

00:51:05.390 --> 00:51:07.075 They did not find any

NOTE Confidence: 0.862903195555556

00:51:07.075 --> 00:51:08.423 obvious predictor of outcome,

NOTE Confidence: 0.862903195555556

00:51:08.430 --> 00:51:11.422 so including an I think on the NGS

NOTE Confidence: 0.862903195555556

00:51:11.422 --> 00:51:14.269 panel or PD1 PDL one expression.

NOTE Confidence: 0.862903195555556

00:51:14.270 --> 00:51:17.390 So there were no clear markers

NOTE Confidence: 0.862903195555556

00:51:17.390 --> 00:51:19.428 of predictive of response.

NOTE Confidence: 0.862903195555556

00:51:19.428 --> 00:51:20.946 So basically uh,

NOTE Confidence: 0.862903195555556

00:51:20.950 --> 00:51:22.560 the things that they highlighted

NOTE Confidence: 0.862903195555556

00:51:22.560 --> 00:51:24.523 was that in this particular scenario

NOTE Confidence: 0.862903195555556

00:51:24.523 --> 00:51:28.742 there were no hyper progression events

NOTE Confidence: 0.862903195555556

00:51:28.742 --> 00:51:31.902 which is reassuring considering that

NOTE Confidence: 0.862903195555556

00:51:31.902 --> 00:51:34.430 single agent checkpoint inhibition

NOTE Confidence: 0.862903195555556

00:51:34.520 --> 00:51:37.698 is really something that we worry

NOTE Confidence: 0.862903195555556

00:51:37.698 --> 00:51:40.115 about immune related side effects did

NOTE Confidence: 0.862903195555556

00:51:40.115 --> 00:51:42.710 occur early and then as I mentioned

NOTE Confidence: 0.862903195555556

00:51:42.710 --> 00:51:46.310 people who had had prior chemotherapy

NOTE Confidence: 0.862903195555556

00:51:46.310 --> 00:51:48.746 did do better in terms of tolerability,  
NOTE Confidence: 0.862903195555556

00:51:48.750 --> 00:51:50.154 tolerability of.  
NOTE Confidence: 0.862903195555556

00:51:50.154 --> 00:51:52.260 Meanwhile, the man.  
NOTE Confidence: 0.862903195555556

00:51:52.260 --> 00:51:54.228 So there were at least two  
NOTE Confidence: 0.862903195555556

00:51:54.228 --> 00:51:55.986 patients who had durable responses  
NOTE Confidence: 0.862903195555556

00:51:55.986 --> 00:51:58.248 in Gamma Delta T cell lymphoma,  
NOTE Confidence: 0.862903195555556

00:51:58.250 --> 00:51:59.638 which is traditionally thought  
NOTE Confidence: 0.862903195555556

00:51:59.638 --> 00:52:01.026 to be very aggressive.  
NOTE Confidence: 0.862903195555556

00:52:01.030 --> 00:52:03.606 And so that again is I think.  
NOTE Confidence: 0.88006775

00:52:05.670 --> 00:52:07.070 One of the reasons that you know,  
NOTE Confidence: 0.88006775

00:52:07.070 --> 00:52:09.820 checkpoint blockade is still being  
NOTE Confidence: 0.88006775

00:52:09.820 --> 00:52:12.570 investigated and RTL inform us.  
NOTE Confidence: 0.88006775

00:52:12.570 --> 00:52:14.490 In the hope of, you know,  
NOTE Confidence: 0.88006775

00:52:14.490 --> 00:52:16.674 finding a particular disease  
NOTE Confidence: 0.88006775

00:52:16.674 --> 00:52:18.858 subtypes that would respond.  
NOTE Confidence: 0.88006775

00:52:18.860 --> 00:52:20.652 So the next paper again is also

NOTE Confidence: 0.88006775

00:52:20.652 --> 00:52:22.440 in the main checkpoint based

NOTE Confidence: 0.88006775

00:52:22.440 --> 00:52:24.825 combination and this one combines

NOTE Confidence: 0.88006775

00:52:24.825 --> 00:52:26.256 pembrolizumab and romidepsin.

NOTE Confidence: 0.88006775

00:52:26.260 --> 00:52:27.900 The prior study was in the front line,

NOTE Confidence: 0.88006775

00:52:27.900 --> 00:52:31.155 this is in relapsed refractory lymphoma and

NOTE Confidence: 0.88006775

00:52:31.155 --> 00:52:34.927 this was this is study out of MD Anderson.

NOTE Confidence: 0.88006775

00:52:34.930 --> 00:52:36.916 So basically again as we mentioned

NOTE Confidence: 0.88006775

00:52:36.916 --> 00:52:39.399 there is a even though there is

NOTE Confidence: 0.88006775

00:52:39.399 --> 00:52:41.219 a risk of hyper progression,

NOTE Confidence: 0.88006775

00:52:41.220 --> 00:52:43.747 there is still reason to study immune

NOTE Confidence: 0.88006775

00:52:43.747 --> 00:52:46.366 checkpoint inhibitor is in cell and formulas.

NOTE Confidence: 0.88006775

00:52:46.366 --> 00:52:48.626 And in this particular scenario

NOTE Confidence: 0.88006775

00:52:48.626 --> 00:52:51.055 they wanted to combine it with

NOTE Confidence: 0.88006775

00:52:51.055 --> 00:52:53.230 an epigenetic modifier that is

NOTE Confidence: 0.88006775

00:52:53.230 --> 00:52:56.290 romidepsin which is an HDAC inhibitor.

NOTE Confidence: 0.88006775

00:52:56.290 --> 00:52:59.755 There is a preclinical data for possible  
NOTE Confidence: 0.88006775

00:52:59.755 --> 00:53:02.323 synergy that's because HDAC inhibitors  
NOTE Confidence: 0.88006775

00:53:02.323 --> 00:53:05.329 do increase PDL one expression and.  
NOTE Confidence: 0.88006775

00:53:05.330 --> 00:53:07.778 So they think that they can,  
NOTE Confidence: 0.88006775

00:53:07.780 --> 00:53:11.770 um, the addition of.  
NOTE Confidence: 0.88006775

00:53:11.770 --> 00:53:14.454 Checkpoint inhibitor will uh.  
NOTE Confidence: 0.88006775

00:53:14.454 --> 00:53:18.480 Promoting will basically in these patients  
NOTE Confidence: 0.88006775

00:53:18.579 --> 00:53:22.029 can help with the improved responses.  
NOTE Confidence: 0.88006775

00:53:22.030 --> 00:53:24.854 So in this study design they had a  
NOTE Confidence: 0.88006775

00:53:24.854 --> 00:53:27.254 phase one lead in for six patients  
NOTE Confidence: 0.88006775

00:53:27.254 --> 00:53:30.116 for as a safety cohort and then they  
NOTE Confidence: 0.88006775

00:53:30.116 --> 00:53:32.989 went ahead with the phase two cohort  
NOTE Confidence: 0.88006775

00:53:32.989 --> 00:53:35.454 and ROMIDEPSIN is traditionally given  
NOTE Confidence: 0.88006775

00:53:35.454 --> 00:53:37.654 day 1815 in this particular study it  
NOTE Confidence: 0.88006775

00:53:37.654 --> 00:53:39.867 was given only on day one and Day 8.  
NOTE Confidence: 0.809778028181818

00:53:43.810 --> 00:53:47.239 I just hear want to highlight that they did



NOTE Confidence: 0.809778028181818

00:53:47.239 --> 00:53:50.320 include a subset of patients that had TFH.

NOTE Confidence: 0.67976703

00:53:52.580 --> 00:53:55.838 Histology like a ITIL which traditionally,

NOTE Confidence: 0.67976703

00:53:55.840 --> 00:53:58.192 and this subset of patients usually

NOTE Confidence: 0.67976703

00:53:58.192 --> 00:53:59.760 responds well to romidepsin.

NOTE Confidence: 0.67976703

00:53:59.760 --> 00:54:02.376 Um, again, they did have two

NOTE Confidence: 0.67976703

00:54:02.376 --> 00:54:04.871 patients who had hyper progression

NOTE Confidence: 0.67976703

00:54:04.871 --> 00:54:09.340 in this particular, OK, so that is.

NOTE Confidence: 0.67976703

00:54:09.340 --> 00:54:12.766 But again it was a minority of

NOTE Confidence: 0.67976703

00:54:12.766 --> 00:54:15.031 patients when considering you know

NOTE Confidence: 0.67976703

00:54:15.031 --> 00:54:18.254 that scene with single agent versus

NOTE Confidence: 0.67976703

00:54:18.254 --> 00:54:20.634 combination of checkpoint inhibition.

NOTE Confidence: 0.67976703

00:54:20.640 --> 00:54:23.420 The overall response rate was

NOTE Confidence: 0.67976703

00:54:23.420 --> 00:54:25.908 47% with the CR rate of 37%.

NOTE Confidence: 0.67976703

00:54:25.908 --> 00:54:28.648 Again, this was a repeated

NOTE Confidence: 0.67976703

00:54:28.648 --> 00:54:30.292 heavily pretreated population,

NOTE Confidence: 0.67976703

00:54:30.300 --> 00:54:35.074 so these are not unexpected numbers and.  
NOTE Confidence: 0.67976703

00:54:35.080 --> 00:54:37.159 This is a Sankey plot that just shows that,  
NOTE Confidence: 0.67976703

00:54:37.160 --> 00:54:39.267 as you can see here, the TFH histologies,  
NOTE Confidence: 0.67976703

00:54:39.267 --> 00:54:42.200 uh, many of them did respond and  
NOTE Confidence: 0.67976703

00:54:42.288 --> 00:54:45.060 get CR after getting Pembroke Romi,  
NOTE Confidence: 0.67976703

00:54:45.060 --> 00:54:46.230 but the response is not,  
NOTE Confidence: 0.67976703

00:54:46.230 --> 00:54:47.025 as you know,  
NOTE Confidence: 0.67976703

00:54:47.025 --> 00:54:49.470 uniform and so some of the other subtypes.  
NOTE Confidence: 0.764009

00:54:52.320 --> 00:54:55.874 So, uh, the median overall survival in  
NOTE Confidence: 0.764009

00:54:55.874 --> 00:55:00.306 this cohort of patients was 21 months and.  
NOTE Confidence: 0.764009

00:55:00.310 --> 00:55:04.830 And the median PFS was 4.8 months with the  
NOTE Confidence: 0.764009

00:55:04.830 --> 00:55:07.889 median duration of response of 36 months.  
NOTE Confidence: 0.764009

00:55:07.889 --> 00:55:10.607 So basically what they found was  
NOTE Confidence: 0.764009

00:55:10.607 --> 00:55:12.260 that even though by absolute  
NOTE Confidence: 0.764009

00:55:12.260 --> 00:55:14.060 numbers it may not seem high,  
NOTE Confidence: 0.764009

00:55:14.060 --> 00:55:15.860 but for T cell lymphomas in this scenario,

NOTE Confidence: 0.764009  
00:55:15.860 --> 00:55:18.188 it did lead to meaningful response  
NOTE Confidence: 0.764009  
00:55:18.188 --> 00:55:20.427 with high response rates and so  
NOTE Confidence: 0.764009  
00:55:20.427 --> 00:55:22.590 they have a larger phase two study  
NOTE Confidence: 0.764009  
00:55:22.590 --> 00:55:27.260 based on this as the next step.  
NOTE Confidence: 0.764009  
00:55:27.260 --> 00:55:29.090 So the next study that I'd  
NOTE Confidence: 0.764009  
00:55:29.090 --> 00:55:30.837 like to highlight was actually  
NOTE Confidence: 0.764009  
00:55:30.837 --> 00:55:33.117 presented by Doctor Francine Foss.  
NOTE Confidence: 0.764009  
00:55:33.120 --> 00:55:35.800 This is a registration trial  
NOTE Confidence: 0.764009  
00:55:35.800 --> 00:55:38.480 for EQUAD for EQUAD 7,  
NOTE Confidence: 0.764009  
00:55:38.480 --> 00:55:41.858 which is an improved formulation of  
NOTE Confidence: 0.764009  
00:55:41.860 --> 00:55:45.234 Deniliquin DeVito X, which is on that.  
NOTE Confidence: 0.764009  
00:55:45.240 --> 00:55:47.624 And this included patients  
NOTE Confidence: 0.764009  
00:55:47.624 --> 00:55:50.008 of relapsed refractory CTCL.  
NOTE Confidence: 0.764009  
00:55:50.010 --> 00:55:52.044 So on tag is a recombinant  
NOTE Confidence: 0.764009  
00:55:52.044 --> 00:55:54.324 protein that has the period toxin  
NOTE Confidence: 0.764009

00:55:54.324 --> 00:55:56.439 and the human interleukin 2.  
NOTE Confidence: 0.8021546

00:55:58.600 --> 00:55:59.370 And.  
NOTE Confidence: 0.8438974375

00:56:01.600 --> 00:56:04.316 Contact was previously taken off the market  
NOTE Confidence: 0.8438974375

00:56:04.316 --> 00:56:06.475 because of manufacturing issues in 2014,  
NOTE Confidence: 0.8438974375

00:56:06.475 --> 00:56:09.795 so this is an improved version of this.  
NOTE Confidence: 0.8438974375

00:56:09.800 --> 00:56:12.590 So basically it has uh two  
NOTE Confidence: 0.8438974375

00:56:12.590 --> 00:56:14.656 different uh ways that it adds it.  
NOTE Confidence: 0.8438974375

00:56:14.660 --> 00:56:16.870 There is direct uh tumor  
NOTE Confidence: 0.8438974375

00:56:16.870 --> 00:56:18.638 cytotoxicity by the ill,  
NOTE Confidence: 0.8438974375

00:56:18.640 --> 00:56:23.505 2 attacking the attaching to the tumor cells  
NOTE Confidence: 0.8438974375

00:56:23.505 --> 00:56:26.730 and the diphtheria toxin acting as the.  
NOTE Confidence: 0.8438974375

00:56:26.730 --> 00:56:29.150 Acting as basically the uh, uh,  
NOTE Confidence: 0.8438974375

00:56:29.150 --> 00:56:32.270 active agent and then it also  
NOTE Confidence: 0.8438974375

00:56:32.270 --> 00:56:35.489 affects the T regs in which.  
NOTE Confidence: 0.8438974375

00:56:35.490 --> 00:56:36.470 Required seven is actually  
NOTE Confidence: 0.8438974375

00:56:36.470 --> 00:56:38.170 decreases in the number of T Rex.

NOTE Confidence: 0.8438974375

00:56:38.170 --> 00:56:40.424 So it's being thought of as a,

NOTE Confidence: 0.8438974375

00:56:40.430 --> 00:56:43.594 it is actually as an immunomodulatory agent.

NOTE Confidence: 0.940421602

00:56:46.670 --> 00:56:48.290 So in this particular case,

NOTE Confidence: 0.940421602

00:56:48.290 --> 00:56:50.875 you know we primarily included

NOTE Confidence: 0.940421602

00:56:50.875 --> 00:56:54.630 patients with city 5 positive,

NOTE Confidence: 0.940421602

00:56:54.630 --> 00:56:59.220 CD, 25 positive tumor with CCR.

NOTE Confidence: 0.940421602

00:56:59.220 --> 00:57:02.728 In relapsed refractory cases.

NOTE Confidence: 0.940421602

00:57:02.730 --> 00:57:05.406 So in terms of response rates,

NOTE Confidence: 0.940421602

00:57:05.410 --> 00:57:08.090 I just you know it showed the response

NOTE Confidence: 0.940421602

00:57:08.090 --> 00:57:10.684 rate was kind of dependent on stage

NOTE Confidence: 0.940421602

00:57:10.684 --> 00:57:13.426 and most of the responses were seen

NOTE Confidence: 0.940421602

00:57:13.426 --> 00:57:15.862 in early stage disease with an

NOTE Confidence: 0.940421602

00:57:15.862 --> 00:57:20.340 overall response rate of 36 to 45%.

NOTE Confidence: 0.940421602

00:57:20.340 --> 00:57:23.268 This just shows you, you know,

NOTE Confidence: 0.940421602

00:57:23.270 --> 00:57:26.203 the one of the things we assess

NOTE Confidence: 0.940421602

00:57:26.203 --> 00:57:27.948 disease responses msport with  
NOTE Confidence: 0.940421602

00:57:27.948 --> 00:57:30.384 looking at the skin tumor burden.  
NOTE Confidence: 0.940421602

00:57:30.390 --> 00:57:33.526 And here we see that the maximum,  
NOTE Confidence: 0.940421602

00:57:33.530 --> 00:57:37.082 you know response again was seen in  
NOTE Confidence: 0.940421602

00:57:37.082 --> 00:57:41.293 48% patients with the 12% achieving CR.  
NOTE Confidence: 0.940421602

00:57:41.293 --> 00:57:44.398 Um, and this swimmers plot  
NOTE Confidence: 0.940421602

00:57:44.398 --> 00:57:47.200 is just delineating.  
NOTE Confidence: 0.940421602

00:57:47.200 --> 00:57:49.630 About 20% patients had prolonged  
NOTE Confidence: 0.940421602

00:57:49.630 --> 00:57:52.560 responses of more than one year.  
NOTE Confidence: 0.940421602

00:57:52.560 --> 00:57:54.306 The main side effects were expected  
NOTE Confidence: 0.940421602

00:57:54.306 --> 00:57:55.880 side effects that are the IL,  
NOTE Confidence: 0.940421602

00:57:55.880 --> 00:57:58.120 two related side effects like  
NOTE Confidence: 0.940421602

00:57:58.120 --> 00:58:00.360 capillary leak syndrome and peripheral  
NOTE Confidence: 0.940421602

00:58:00.429 --> 00:58:03.039 edema as well as some transaminitis  
NOTE Confidence: 0.940421602

00:58:03.039 --> 00:58:04.779 and infusion related reaction.  
NOTE Confidence: 0.940421602

00:58:04.780 --> 00:58:08.777 So again you know overall this is

NOTE Confidence: 0.940421602

00:58:08.777 --> 00:58:12.800 an active agent in CTCL and again

NOTE Confidence: 0.940421602

00:58:12.800 --> 00:58:14.720 it is a possible improvement over

NOTE Confidence: 0.940421602

00:58:14.720 --> 00:58:17.280 on tag and this was a registration.

NOTE Confidence: 0.940421602

00:58:17.280 --> 00:58:19.760 30 and it has been.

NOTE Confidence: 0.940421602

00:58:19.760 --> 00:58:23.160 The initial application is accepted

NOTE Confidence: 0.940421602

00:58:23.160 --> 00:58:27.410 for approval for review.

NOTE Confidence: 0.940421602

00:58:27.410 --> 00:58:29.130 So I think at this point it's uh,

NOTE Confidence: 0.940421602

00:58:29.130 --> 00:58:32.595 since it's one o'clock, I'm going to.

NOTE Confidence: 0.940421602

00:58:32.600 --> 00:58:35.250 Stop here.

NOTE Confidence: 0.940421602

00:58:35.250 --> 00:58:38.806 And basically the Hotchkin you know cases,

NOTE Confidence: 0.940421602

00:58:38.810 --> 00:58:40.784 the abstracts that I wanted to talk

NOTE Confidence: 0.940421602

00:58:40.784 --> 00:58:42.772 about were nibo ice that was found

NOTE Confidence: 0.940421602

00:58:42.772 --> 00:58:44.398 to be pretty effective in high

NOTE Confidence: 0.940421602

00:58:44.455 --> 00:58:46.167 risk Hodgkin lymphoma patients.

NOTE Confidence: 0.940421602

00:58:46.170 --> 00:58:48.249 And the other one is a combination

NOTE Confidence: 0.940421602

00:58:48.249 --> 00:58:50.806 of a newer agent and anti lag 3  
NOTE Confidence: 0.940421602

00:58:50.806 --> 00:58:54.429 antibody with with pembrolizumab and  
NOTE Confidence: 0.940421602

00:58:54.430 --> 00:58:56.830 but in the interest of time I will stop here.  
NOTE Confidence: 0.940421602

00:58:56.830 --> 00:58:57.090 Thanks.  
NOTE Confidence: 0.808666113076923

00:58:59.170 --> 00:59:01.807 So I wanted to thank all three of the  
NOTE Confidence: 0.808666113076923

00:59:01.807 --> 00:59:03.783 panelists for really selecting highest  
NOTE Confidence: 0.808666113076923

00:59:03.783 --> 00:59:06.394 priority and impact abstracts and doing a  
NOTE Confidence: 0.808666113076923

00:59:06.394 --> 00:59:08.547 great job summarizing that all panelists  
NOTE Confidence: 0.808666113076923

00:59:08.547 --> 00:59:11.698 are able to stay for a few more minutes.  
NOTE Confidence: 0.808666113076923

00:59:11.700 --> 00:59:13.452 And so I thought we'd have a little  
NOTE Confidence: 0.808666113076923

00:59:13.452 --> 00:59:15.148 bit of question answer period,  
NOTE Confidence: 0.808666113076923

00:59:15.150 --> 00:59:16.218 some great questions coming  
NOTE Confidence: 0.808666113076923

00:59:16.218 --> 00:59:17.286 in from doctor nepotism.  
NOTE Confidence: 0.808666113076923

00:59:17.290 --> 00:59:20.440 But first I I had a question  
NOTE Confidence: 0.808666113076923

00:59:20.440 --> 00:59:21.790 for Doctor Motonari.  
NOTE Confidence: 0.808666113076923

00:59:21.790 --> 00:59:24.078 You know with the augment long term data



NOTE Confidence: 0.808666113076923  
00:59:24.078 --> 00:59:26.433 and with really encouraging data with by  
NOTE Confidence: 0.808666113076923  
00:59:26.433 --> 00:59:28.980 specifics a lot of patients with locular,  
NOTE Confidence: 0.808666113076923  
00:59:28.980 --> 00:59:31.302 the non high risk patients are  
NOTE Confidence: 0.808666113076923  
00:59:31.302 --> 00:59:33.239 actually getting rituximab first line  
NOTE Confidence: 0.808666113076923  
00:59:33.239 --> 00:59:35.493 R chemo often our vendor second line.  
NOTE Confidence: 0.808666113076923  
00:59:35.500 --> 00:59:37.516 And how do you think about third  
NOTE Confidence: 0.808666113076923  
00:59:37.516 --> 00:59:39.000 line for those patients?  
NOTE Confidence: 0.808666113076923  
00:59:39.000 --> 00:59:40.440 Do you think about our square,  
NOTE Confidence: 0.808666113076923  
00:59:40.440 --> 00:59:41.760 do you think about bispecific,  
NOTE Confidence: 0.808666113076923  
00:59:41.760 --> 00:59:42.453 how do you,  
NOTE Confidence: 0.808666113076923  
00:59:42.453 --> 00:59:44.399 how do you actually you know without the  
NOTE Confidence: 0.808666113076923  
00:59:44.399 --> 00:59:46.338 data we don't really have randomized data.  
NOTE Confidence: 0.808666113076923  
00:59:46.340 --> 00:59:48.132 How are you going to approach those cases  
NOTE Confidence: 0.808666113076923  
00:59:48.132 --> 00:59:49.699 which will be actually quite common.  
NOTE Confidence: 0.777716543571429  
00:59:51.330 --> 00:59:53.591 Very good question and I think this  
NOTE Confidence: 0.777716543571429

00:59:53.591 --> 00:59:56.249 is by just my my personal opinion,  
NOTE Confidence: 0.777716543571429

00:59:56.250 --> 00:59:58.395 I don't think we're going  
NOTE Confidence: 0.777716543571429

00:59:58.395 --> 01:00:01.020 to be given data on the.  
NOTE Confidence: 0.777716543571429

01:00:01.020 --> 01:00:02.592 The sequential treatment meaning  
NOTE Confidence: 0.777716543571429

01:00:02.592 --> 01:00:05.409 what would be the outcome in patients  
NOTE Confidence: 0.777716543571429

01:00:05.409 --> 01:00:08.160 receiving our square as second line and  
NOTE Confidence: 0.777716543571429

01:00:08.160 --> 01:00:10.557 the patients followed by by specific.  
NOTE Confidence: 0.777716543571429

01:00:10.560 --> 01:00:13.598 Most of the clinical trials that are  
NOTE Confidence: 0.777716543571429

01:00:13.598 --> 01:00:16.619 now ongoing tend to combine our square  
NOTE Confidence: 0.777716543571429

01:00:16.619 --> 01:00:19.170 with the with or without The Dirty  
NOTE Confidence: 0.777716543571429

01:00:19.170 --> 01:00:21.580 taxi with the by specific antibody.  
NOTE Confidence: 0.777716543571429

01:00:21.580 --> 01:00:25.060 So you know when we combine these treatment  
NOTE Confidence: 0.777716543571429

01:00:25.060 --> 01:00:28.332 we always get into a little bit more  
NOTE Confidence: 0.777716543571429

01:00:28.332 --> 01:00:31.109 toxicity and I'm not sure that all.  
NOTE Confidence: 0.777716543571429

01:00:31.110 --> 01:00:33.978 Nations that would benefit from an  
NOTE Confidence: 0.777716543571429

01:00:33.978 --> 01:00:35.890 intensification of treatment earlier

NOTE Confidence: 0.777716543571429

01:00:35.963 --> 01:00:38.923 on uh what we really need is good

NOTE Confidence: 0.777716543571429

01:00:38.923 --> 01:00:40.506 prognostication model to really

NOTE Confidence: 0.777716543571429

01:00:40.506 --> 01:00:42.426 risk stratify these patients up

NOTE Confidence: 0.777716543571429

01:00:42.426 --> 01:00:44.588 front and guide us in the selection.

NOTE Confidence: 0.777716543571429

01:00:44.588 --> 01:00:46.804 But for now I think it would be

NOTE Confidence: 0.777716543571429

01:00:46.804 --> 01:00:48.399 content to just the sequence,

NOTE Confidence: 0.777716543571429

01:00:48.400 --> 01:00:50.800 the treatment that they are available

NOTE Confidence: 0.777716543571429

01:00:50.800 --> 01:00:52.942 with our square followed by a

NOTE Confidence: 0.777716543571429

01:00:52.942 --> 01:00:54.013 by specific antibody.

NOTE Confidence: 0.777716543571429

01:00:54.020 --> 01:00:55.672 Certainly after reviewing this

NOTE Confidence: 0.777716543571429

01:00:55.672 --> 01:00:58.953 data card in my mind is pushed a

NOTE Confidence: 0.777716543571429

01:00:58.953 --> 01:01:01.230 little bit over in the future for.

NOTE Confidence: 0.777716543571429

01:01:01.230 --> 01:01:02.650 Participation population.

NOTE Confidence: 0.839647679333333

01:01:03.940 --> 01:01:05.176 Yeah, I think that's a really

NOTE Confidence: 0.839647679333333

01:01:05.176 --> 01:01:06.000 helpful response and exactly

NOTE Confidence: 0.839647679333333

01:01:06.043 --> 01:01:06.968 what I'm thinking as well.  
NOTE Confidence: 0.8396476793333333

01:01:06.970 --> 01:01:09.024 There may be some slight, you know,  
NOTE Confidence: 0.8396476793333333

01:01:09.024 --> 01:01:11.256 select patient populations where you have  
NOTE Confidence: 0.8396476793333333

01:01:11.256 --> 01:01:13.329 toxicity concerns whether it be renal  
NOTE Confidence: 0.8396476793333333

01:01:13.329 --> 01:01:15.237 dysfunction with line things like that.  
NOTE Confidence: 0.8396476793333333

01:01:15.240 --> 01:01:17.487 But the R-squared data is quite compelling  
NOTE Confidence: 0.8396476793333333

01:01:17.487 --> 01:01:19.073 with that particularly that freedom  
NOTE Confidence: 0.8396476793333333

01:01:19.073 --> 01:01:20.777 from next treatment of 70 months.  
NOTE Confidence: 0.8396476793333333

01:01:20.780 --> 01:01:23.388 So I I think that sequence is here  
NOTE Confidence: 0.8396476793333333

01:01:23.388 --> 01:01:26.295 to stay at least for the time being.  
NOTE Confidence: 0.8396476793333333

01:01:26.300 --> 01:01:30.560 There's a important question to to all of us,  
NOTE Confidence: 0.8396476793333333

01:01:30.560 --> 01:01:32.310 but really directed to Doctor  
NOTE Confidence: 0.8396476793333333

01:01:32.310 --> 01:01:34.060 Cathari about what's you know,  
NOTE Confidence: 0.8396476793333333

01:01:34.060 --> 01:01:34.880 where do we go with.  
NOTE Confidence: 0.8396476793333333

01:01:34.880 --> 01:01:38.610 First line DLBCL in 2023,  
NOTE Confidence: 0.8396476793333333

01:01:38.610 --> 01:01:41.742 you know we'll likely hear about Paul R Chip,

NOTE Confidence: 0.839647679333333

01:01:41.750 --> 01:01:44.198 but I thought your data actually

NOTE Confidence: 0.839647679333333

01:01:44.198 --> 01:01:46.086 of using our chop and then epoch

NOTE Confidence: 0.839647679333333

01:01:46.086 --> 01:01:47.414 and then giving some centering

NOTE Confidence: 0.839647679333333

01:01:47.414 --> 01:01:49.184 was quite compelling for the the

NOTE Confidence: 0.839647679333333

01:01:49.184 --> 01:01:50.710 high grade double hit patient.

NOTE Confidence: 0.839647679333333

01:01:50.710 --> 01:01:53.377 So how how are you thinking about

NOTE Confidence: 0.839647679333333

01:01:53.377 --> 01:01:55.342 approaching your non double hit

NOTE Confidence: 0.839647679333333

01:01:55.342 --> 01:01:57.480 and double hit patients in 2023?

NOTE Confidence: 0.83957614

01:01:58.150 --> 01:02:01.468 Yeah. Very difficult question to answer,

NOTE Confidence: 0.83957614

01:02:01.470 --> 01:02:04.550 mainly because we don't have direct data,

NOTE Confidence: 0.83957614

01:02:04.550 --> 01:02:06.886 but we can put few pieces together and

NOTE Confidence: 0.83957614

01:02:06.886 --> 01:02:09.710 come up with a treatment plan, I guess.

NOTE Confidence: 0.83957614

01:02:09.710 --> 01:02:13.354 So my strategy would be that if the patient

NOTE Confidence: 0.83957614

01:02:13.354 --> 01:02:17.260 is a denovo DLBCL with IPI score of three

NOTE Confidence: 0.83957614

01:02:17.354 --> 01:02:20.621 to five and it does not have a double

NOTE Confidence: 0.83957614

01:02:20.621 --> 01:02:23.410 hit disease or double expressor disease,  
NOTE Confidence: 0.83957614

01:02:23.410 --> 01:02:26.908 then I would still be more,  
NOTE Confidence: 0.83957614

01:02:26.910 --> 01:02:29.061 you know, favorable.  
NOTE Confidence: 0.83957614

01:02:29.061 --> 01:02:31.929 Favor of Pola RCHP.  
NOTE Confidence: 0.83957614

01:02:31.930 --> 01:02:34.442 If it comes to a patient where we  
NOTE Confidence: 0.83957614

01:02:34.442 --> 01:02:36.522 are worried about double expressor  
NOTE Confidence: 0.83957614

01:02:36.522 --> 01:02:38.358 and double hit disease.  
NOTE Confidence: 0.83957614

01:02:38.360 --> 01:02:40.950 I I I would think that you know I would  
NOTE Confidence: 0.83957614

01:02:41.024 --> 01:02:43.778 definitely put in a lot of weight to this  
NOTE Confidence: 0.83957614

01:02:43.778 --> 01:02:46.176 dose escalation strategy where there  
NOTE Confidence: 0.83957614

01:02:46.176 --> 01:02:48.444 is incorporation of high dose methotrexate,  
NOTE Confidence: 0.83957614

01:02:48.450 --> 01:02:52.212 there is incorporation of R epoch  
NOTE Confidence: 0.83957614

01:02:52.212 --> 01:02:54.720 followed by hydro cytarabine.  
NOTE Confidence: 0.83957614

01:02:54.720 --> 01:02:57.018 I think the data is very  
NOTE Confidence: 0.83957614

01:02:57.018 --> 01:02:58.550 compelling as you said.  
NOTE Confidence: 0.83957614

01:02:58.550 --> 01:03:00.998 In and I think Doctor Nepri

NOTE Confidence: 0.83957614

01:03:00.998 --> 01:03:02.870 also asked regarding how I,

NOTE Confidence: 0.83957614

01:03:02.870 --> 01:03:04.825 how I would approach subgroups

NOTE Confidence: 0.83957614

01:03:04.825 --> 01:03:06.172 of these DLBCL.

NOTE Confidence: 0.83957614

01:03:06.172 --> 01:03:10.668 And you know at at in this current

NOTE Confidence: 0.83957614

01:03:10.668 --> 01:03:14.492 time all so far all the trials that

NOTE Confidence: 0.83957614

01:03:14.492 --> 01:03:16.724 were designed to primarily study

NOTE Confidence: 0.83957614

01:03:16.724 --> 01:03:18.809 these subgroups have been negative.

NOTE Confidence: 0.83957614

01:03:18.810 --> 01:03:22.090 So for example Phoenix trial very

NOTE Confidence: 0.83957614

01:03:22.090 --> 01:03:24.130 compelling results when you you know

NOTE Confidence: 0.83957614

01:03:24.130 --> 01:03:26.340 further tease out these molecular subgroups

NOTE Confidence: 0.83957614

01:03:26.340 --> 01:03:28.602 for example in the Phoenix trial.

NOTE Confidence: 0.83957614

01:03:28.610 --> 01:03:31.005 MCD subgroup did phenomenally well

NOTE Confidence: 0.83957614

01:03:31.005 --> 01:03:34.260 when ibrutinib was added to our chalk.

NOTE Confidence: 0.83957614

01:03:34.260 --> 01:03:37.564 Similarly the data that I presented of

NOTE Confidence: 0.83957614

01:03:37.564 --> 01:03:40.820 adding Bortezomib to our chop in ABC DLBCL.

NOTE Confidence: 0.83957614

01:03:40.820 --> 01:03:43.802 But the reality is that in clinic  
NOTE Confidence: 0.83957614

01:03:43.802 --> 01:03:45.842 gene expression profiling is very  
NOTE Confidence: 0.83957614

01:03:45.842 --> 01:03:48.562 challenging to do and I think we really  
NOTE Confidence: 0.83957614

01:03:48.635 --> 01:03:50.975 need to put in a lot of effort as  
NOTE Confidence: 0.83957614

01:03:50.975 --> 01:03:55.020 as as a group of clinicians to have  
NOTE Confidence: 0.83957614

01:03:55.020 --> 01:03:58.592 better clinical modalities to to.  
NOTE Confidence: 0.83957614

01:03:58.592 --> 01:04:02.382 Risk stratify patients by gene,  
NOTE Confidence: 0.83957614

01:04:02.390 --> 01:04:06.098 by genetic makeup in the clinic,  
NOTE Confidence: 0.83957614

01:04:06.100 --> 01:04:08.256 if not by diagnosis then at least  
NOTE Confidence: 0.83957614

01:04:08.256 --> 01:04:10.308 by the end of first cycle,  
NOTE Confidence: 0.83957614

01:04:10.310 --> 01:04:12.614 so that we can change strategy  
NOTE Confidence: 0.83957614

01:04:12.614 --> 01:04:13.766 second cycle onwards.  
NOTE Confidence: 0.57098172

01:04:17.230 --> 01:04:18.634 That's really helpful.  
NOTE Confidence: 0.57098172

01:04:18.634 --> 01:04:21.424 And and I guess what you're getting at  
NOTE Confidence: 0.57098172

01:04:21.424 --> 01:04:23.480 is a dynamic biomarker whether it be  
NOTE Confidence: 0.57098172

01:04:23.480 --> 01:04:25.955 you know self for DNA and and or kind



NOTE Confidence: 0.57098172

01:04:25.955 --> 01:04:27.923 of reduction in the circling disease.

NOTE Confidence: 0.57098172

01:04:27.930 --> 01:04:31.188 There's a question from the audience.

NOTE Confidence: 0.57098172

01:04:31.190 --> 01:04:33.910 It kind of I think broadly in inductive

NOTE Confidence: 0.57098172

01:04:33.910 --> 01:04:35.944 Montanari kind of alluded to it

NOTE Confidence: 0.57098172

01:04:35.944 --> 01:04:37.870 trying to think about by specifics

NOTE Confidence: 0.57098172

01:04:37.940 --> 01:04:40.181 versus cellular therapy car T tarsin.

NOTE Confidence: 0.57098172

01:04:40.181 --> 01:04:43.017 Can you help us with you know that

NOTE Confidence: 0.57098172

01:04:43.017 --> 01:04:44.830 thought right now it's really just in

NOTE Confidence: 0.57098172

01:04:44.890 --> 01:04:46.846 follicular but certainly there will be

NOTE Confidence: 0.57098172

01:04:46.846 --> 01:04:49.068 more data with bispecific and large Sonoma.

NOTE Confidence: 0.57098172

01:04:49.070 --> 01:04:51.077 How do you how do you kind of think

NOTE Confidence: 0.57098172

01:04:51.077 --> 01:04:53.260 about those modalities for your patients?

NOTE Confidence: 0.881428109444445

01:04:54.270 --> 01:04:56.034 Yeah, I think right now it's

NOTE Confidence: 0.881428109444445

01:04:56.034 --> 01:04:57.840 such a dynamic field and which

NOTE Confidence: 0.881428109444445

01:04:57.840 --> 01:04:59.836 is which we are thankful for to

NOTE Confidence: 0.881428109444445

01:04:59.836 --> 01:05:01.266 have all these different options.  
NOTE Confidence: 0.881428109444445

01:05:01.270 --> 01:05:03.706 But I would think that you know  
NOTE Confidence: 0.881428109444445

01:05:03.710 --> 01:05:06.326 Carter cell therapy I think in  
NOTE Confidence: 0.881428109444445

01:05:06.330 --> 01:05:09.270 is definitely more involved.  
NOTE Confidence: 0.881428109444445

01:05:09.270 --> 01:05:11.699 And also there's often a delay because  
NOTE Confidence: 0.881428109444445

01:05:11.699 --> 01:05:13.913 there's no still the options we have  
NOTE Confidence: 0.881428109444445

01:05:13.913 --> 01:05:16.150 are not off the shelf uh options.  
NOTE Confidence: 0.881428109444445

01:05:16.150 --> 01:05:17.634 So there's a delay in you know  
NOTE Confidence: 0.881428109444445

01:05:17.634 --> 01:05:18.840 getting these patients to treatment.  
NOTE Confidence: 0.881428109444445

01:05:18.840 --> 01:05:22.304 So I think having the option of bias  
NOTE Confidence: 0.881428109444445

01:05:22.304 --> 01:05:24.210 specifics really I really don't think  
NOTE Confidence: 0.881428109444445

01:05:24.210 --> 01:05:25.770 that one would replace the other.  
NOTE Confidence: 0.881428109444445

01:05:25.770 --> 01:05:27.730 I really think that they are both important,  
NOTE Confidence: 0.881428109444445

01:05:27.730 --> 01:05:30.298 but I think having the the option of  
NOTE Confidence: 0.881428109444445

01:05:30.298 --> 01:05:32.736 by specifics as as an off the shelf  
NOTE Confidence: 0.881428109444445

01:05:32.736 --> 01:05:34.921 option will avoid the delays that we

NOTE Confidence: 0.881428109444445  
01:05:34.921 --> 01:05:37.168 usually see and then also would be  
NOTE Confidence: 0.881428109444445  
01:05:37.170 --> 01:05:39.276 reasonable options for maybe even older.  
NOTE Confidence: 0.881428109444445  
01:05:39.280 --> 01:05:41.600 Individuals that sometimes are not  
NOTE Confidence: 0.881428109444445  
01:05:41.600 --> 01:05:43.920 candidates for Karti cell therapy.  
NOTE Confidence: 0.7700939  
01:05:45.960 --> 01:05:47.985 Yeah, it's it's clear that by  
NOTE Confidence: 0.7700939  
01:05:47.985 --> 01:05:49.710 specifics are being moved up  
NOTE Confidence: 0.826370725714286  
01:05:49.784 --> 01:05:51.380 earlier into first line,  
NOTE Confidence: 0.826370725714286  
01:05:51.380 --> 01:05:54.838 so follicular pharma for large volume comma.  
NOTE Confidence: 0.826370725714286  
01:05:54.840 --> 01:05:57.280 So you know I was reminded that it's  
NOTE Confidence: 0.826370725714286  
01:05:57.280 --> 01:05:59.793 actually it was 25 year anniversary of  
NOTE Confidence: 0.826370725714286  
01:05:59.793 --> 01:06:02.057 rituximab being approved and to think  
NOTE Confidence: 0.826370725714286  
01:06:02.057 --> 01:06:04.897 about in the last three years all the  
NOTE Confidence: 0.826370725714286  
01:06:04.897 --> 01:06:06.276 biospecifics being developed and how  
NOTE Confidence: 0.826370725714286  
01:06:06.276 --> 01:06:08.380 fast this is moving is pretty remarkable.  
NOTE Confidence: 0.826370725714286  
01:06:08.380 --> 01:06:13.060 So I'm sure we'll have lots of  
NOTE Confidence: 0.826370725714286

01:06:13.060 --> 01:06:15.910 dents CME post ash meetings.

NOTE Confidence: 0.826370725714286

01:06:15.910 --> 01:06:17.458 For the coming years as well,

NOTE Confidence: 0.826370725714286

01:06:17.460 --> 01:06:19.316 but I want to thank our presenters and

NOTE Confidence: 0.826370725714286

01:06:19.316 --> 01:06:21.163 and thank all of you for joining and

NOTE Confidence: 0.826370725714286

01:06:21.163 --> 01:06:22.880 I hope everyone has a great weekend.

NOTE Confidence: 0.96436745

01:06:24.990 --> 01:06:27.000 Thank you.